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Inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) 
are two highly aggressive breast cancer subtypes associated with a poor outcome. 
Despite sensitivity to current treatment, these breast cancers subtypes have a high 
recurrence rate and proclivity to metastasize early. The aggressiveness of IBC and 
TNBC have been linked to CSCs and epithelial to mesenchymal transition (EMT), 
which are critical features of breast cancer progression and metastasis. The clinical 
challenge faced in the treatment of IBC and TNBC is finding a treatment strategy to 
target the cancer stem-like (CSC) population to block metastasis. Cyclooxygenase-2 
(COX-2) and receptor activator of nuclear factor kappa B ligand/receptor activator of 
nuclear factor kappa B (RANKL/RANK) pathway mediate an inflammatory response 
linked to breast cancer progression. However, the mechanism of how COX-2 and 
RANKL/RANK regulates the progression of IBC and TNBC, respectively, is unclear. 
Therefore, we investigated COX-2 and RANKL/RANK in IBC and TNBC. We 
hypothesize that targeted inhibition of COX-2 and RANK in IBC and TNBC, 
respectively, could eradicate CSCs to suppress tumor progression. 
We observed elevated COX-2 levels in EGFR-positive IBC cells and a 
significant correlation between COX-2 and EGFR gene expression in IBC tumors. How 
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COX-2 linked to CSCs and regulates IBC progression is not well understood. We 
hypothesize COX-2 to be critical for IBC progression through regulation of the CSC 
population. Celecoxib, a selective COX-2 inhibitor, has anti-tumorigenic effects by 
reducing breast cancer cell migration and invasion. Celecoxib treatment in an IBC 
xenograft mouse model reversed EMT and downregulated expression of the embryonic 
stem cell regulator Nodal.  We concluded COX-2 regulation of the CSCs through Nodal 
contributed to the progression of IBC and targeting the COX-2 has clinical relevance in 
blocking the progression of IBC.  
RANKL/RANK pathway promotes the invasion, EMT and mammary epithelial 
stem cell population. We observed elevated expression in TNBC tumors and RANKL to 
be an independent prognostic factor for worse outcome in RANK-positive TNBC 
patients. How RANK promotes TNBC progression is not clear. We hypothesize that 
suppression of RANK inhibits TNBC progression through eradication of CSCs. We 
observed the suppression of RANK to reduce MDA-MB-231 cell migration and 
invasion, and mammosphere formation. Stem cell genes, implicated in inflammatory 
signaling, were down-regulated in MDA-MB-231 RANK shRNA cells.  
Collectively, our findings suggest COX-2 and RANK to regulate of CSCs in IBC 
and TNBC potentially through mediating an inflammatory response. Future pre-clinical 
studies are needed to further interrogate COX-2 and RANK as novel therapeutic 
targets for IBC and TNBC. 
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CHAPTER 1: INTRODUCTION 
1.1 BREAST CANCER 
 
For 2014, it is predicted that about 235,000 new cases of breast cancer will be 
diagnosed, and about 40,000 breast cancer patients are expected to die from the 
disease (1). While we are making advancements in breast cancer treatments, we are 
still met with the challenge of finding treatments to inhibit metastasis, a leading cause 
of death in breast cancer patients. Breast cancer metastasis is a complex process 
preceded by the development of resistance to treatment or recurrence which is often 
associated with aggressive breast cancer subtypes. The multistage progression of 
breast cancer is as follows: 1) normal mammary cells, 2) atypical ductal hyperplasia, 3) 
ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), 4) invasive breast 
cancer, and 5) metastatic breast cancer (2, 3). While stage I and II breast cancer 
patients have a better prognosis, the locally advanced and metastatic breast cancers 
stage III and IV, have a poorer prognosis (4). The current treatment strategy for 
advanced stage breast cancers includes doxorubicin or taxane-based neoadjuvant 
chemotherapy followed by surgery and adjuvant chemotherapy paclitaxel and/or 
anthracycline. Patients may also receive radiotherapy and/or hormone receptor 
targeted therapy (5). Depending upon the molecular breast cancer subtype, luminal, 
basal-like, or normal, hormone receptor targeted therapy may be administered as part 
of the treatment regimen. Breast tumors associated with a particular intrinsic molecular 
subtype, luminal (non-HER2-positive), HER2-positive, basal-like, or triple-negative, 
express molecular markers, EGFR, ER and/or HER2, which can be targeted for 
treatment (6, 7). As a basal marker and molecular therapeutic target of interest for 
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aggressive breast cancers, the epidermal growth factor receptor (EGFR) is under 
intense investigation.  
1.2 EPIDERMAL GROWTH FACTOR RECEPTOR 
 
Since the first discovery of gene amplification of the epidermal growth factor 
receptor (EGFR) in breast cancer, significant progress has been made in our 
understanding of the EGFR 
signaling pathway and its role in 
breast cancer tumorigenesis 
and progression (8). The 
activation of the EGFR pathway 
may occur through different 
growth factor ligands that bind 
to the receptor to induce the 
downstream activation of key 
regulators of cell growth, 
proliferation, invasion, and 
metastasis. The PI3K/AKT and 
MAPK signaling pathways 
activated by EGFR promotes 
the progression of breast cancer (illustration 1.2) (9). There are several mechanisms by 
which EGFR-mediated tumorigenesis and metastasis can occur including, EGFR gene 
amplification, heterodimerization with HER2, and activating mutations, in breast cancer. 
Greater than 50% of breast tumors have EGFR amplification, and EGFR has been 
ILLUSTRATION 1.2 EPIDERMAL GROWTH 
FACTOR RECEPTOR SIGNALING 
The process of EGF-EGFR and EGFR-EGFR 
interaction activates the PI3K/AKT and MAPK 
signaling pathways which promote malignant 
behavior critical to breast cancer progression. 
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shown to contribute to the invasiveness of breast cancers and the stem cell phenotype 
in breast cancer (10). In the basal-like breast cancer subtype, greater than 50% of 
tumors have an overexpression of EGFR (10). Highly aggressive triple-negative breast 
cancer (TNBC) and inflammatory breast cancer (IBC) subtypes, characterized by 
advanced and less-differentiated histological features associated with a poorer 
prognosis, have an overexpression of EGFR in approximately 30 to 50% of tumors (9, 
11). Although it is unknown whether EGFR is a predictive marker for TNBC or IBC, 
EGFR expression levels are being utilized in treatment studies for patient selection (9), 
and EGFR-targeted therapies, lapatinib, erlotinib, and panitumumab, are currently 
being exploited in TNBC and IBC (12, 13).  
1.3 TRIPLE-NEGATIVE BREAST CANCER  
 
TNBC is an aggressive disease that is commonly diagnosed in younger women 
between the ages of 30-40 years, and has a high tendency to develop resistance to 
standard chemotherapy and metastasize (14). TNBC makes up about 30% of all breast 
cancers diagnosed, and about 40% of the basal-like subtype. Based on the intrinsic 
gene expression profile described by Bertucci F.et al., approximately 80% of TNBC 
tumors are considered to be basal tumors (15). Both TNBC and basal tumors are 
described as having genetic mutations in DNA repair proteins such as, P53, and 
BRCA1, and amplification of oncogenes, c-myc, and EGFR (16). Although there is an 
overlap between TNBC and basal tumors in gene expression profiles, there is 
controversy surrounding the concept that all TNBC tumors are basal tumors. 
Histoclinical and molecular differences were detected between basal and non-basal 
TNBCs but not between TNBC and non-TNBC basal tumors, which implies TNBC 
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tumors to have a higher degree of heterogeneity than basal tumors. In a gene 
expression profiling study conducted by Lehmann B.D. et al, it was observed that 
TNBC can be classified based on transcriptional profiles described in the TNBC 
subtypes: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal 
(M), mesenchymal stem-like (MSL), luminal androgen receptor (LAR), and unstable 
(UNS) (17). Masuda H. et al. predicted the BL1 and MSL TNBC subtypes to be the 
predominant subtypes in IBC because of the highly aggressive gene expression 
profiles inclusive of increased cell proliferative markers (i.e. Ki67), and EMT markers 
(17). Not only did both studies confirm the heterogeneity of TNBC but they also 
confirmed gene expression linked with an inflammatory response. Indeed, a signature 
of transforming growth factor β (TGFβ) activation was identified in the M and MSL 
subtypes, while the expression of growth factor signaling molecules including EGFR 
was up-regulated in the BL2 and MSL subtypes (12). These findings confirm the TNBC 
subtype to be enriched with an inflammatory and metastatic gene expression profiles 
which includes BMP2 and ALDH1 mesenchymal stem cell markers.  (12). 
Metastasis occurs in a higher proportion of TNBC patients than ER+/HER2+  
breast cancer patients, at approximately 33% and 20%, respectively (18). Unlike 
luminal and HER2-positive breast cancers, which express ER and HER2, TNBC lacks 
clinically-validated, markers and targeted therapeutics. Depending upon tumor stage, 
size, grade, and the presence of invasive disease at diagnosis, TNBC  patients may 
receive a treatment regimen including neoadjuvant chemotherapy, surgery, and 
adjuvant chemotherapy and radiation therapy (4). Initially, TNBC tumors are sensitive 
to chemotherapy and radiation; however, they eventually develop resistance to 
treatment resulting in locoregional or distant recurrence.  
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Patients with EGFR-positive TNBC are associated with a poor response to 
chemotherapy alone (19). To address this issue, there have been a number of studies 
that investigated a combination approach of targeting EGFR with systemic therapy to 
delay TNBC progression (20). In a clinical phase II study for patients with late-stage 
metastatic TNBC treated with cetuximab alone or in combination with carboplatin 
resulted in a higher response rate in those that received combination treatment. 
Regardless of this difference,  a majority of patients had activated EGFR pathway 
following treatment suggesting that either cetuximab was not effective or the EGFR 
pathway is activated, by another pathway independently of its ligand in these tumors 
(21, 22). In a phase II clinical study of panitumumab, a fully humanized EGFR-specific 
monoclonal antibody, with anthracycline and taxane-based chemotherapy in TNBC, a 
higher response rate and longer progression-free survival was observed (23). Despite 
the findings that EGFR-targeted therapy with systemic therapy maybe a more 
beneficial therapeutic strategy for TNBC patients, we do not have a clear 
understanding of the progression of TNBC. It is likely that breast tumors that do not 
respond to EGFR-targeted therapy may benefit from other targeted therapy. In light of 
the recent discovery that TNBC heterogeneity can be classified based on molecularly 
defined subtypes, it is predicted that TNBC tumors belonging to one subtype may be 
more responsive to a particular therapy over another (12). For instance, TNBC 
expressing mutated BRCA1 or p53 appear to have increased sensitivity to PARP 
inhibitors, including those with elevated immune signaling pathways (12). Thus, there 
are several clinically-relevant and targetable pathways in certain types of TNBC, which 
may help to block progression of the disease and improve survival in TNBC patients. 
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1.4 INFLAMMATORY BREAST CANCER (IBC)  
 
Inflammatory breast cancer (IBC) is an aggressive breast cancer, which makes 
up approximately 1-5% of all breast cancers diagnosed in the U.S. It is one of the 
deadliest breast cancers, and comprises approximately 8-10% of total breast cancer 
mortality rate in the United States (24-26). Despite the fact that IBC is diagnosed as 
being a locally advanced and highly invasive breast cancer with inflammatory-like 
symptoms including erythema and edema, a molecular mechanism of a physiologic 
inflammatory response has not yet been identified in IBC. The clinical manifestations 
presented in IBC patients include: erythema, edema, peau d’ orange, and breast 
swelling with pain or tenderness (27). In addition, IBC patients may or may not present 
with a palpable mass (28). A majority of IBC patients have lymph node metastasis and 
30% have distant metastasis at the time of diagnosis (28). Another clinical 
manifestation presented in IBC patients is dermal lymphatic tumor emboli, which is 
identified  by a skin-punch biopsy (29). The current treatment strategy for IBC is a 
multimodality approach, which includes pre-operative standard chemotherapy and 
radiation therapy, surgery and adjuvant therapy, inclusive of hormone-targeted therapy 
(4). Treatment with adjuvant or neoadjuvant hormone receptor therapy, such as 
trastuzumab or tamoxifen, is provided to patients with IBC tumors that express HER2 
or ER, respectively. Although some IBC tumors respond to current treatment, there is 
the dilemma of local and distant recurrence, which needs to be addressed by 
investigating molecular targeted therapies (30).  
As represented in about 30% of IBC, the overexpression of EGFR is associated 
with high risk of recurrence and low 5-year overall survival (9, 31). The use of EGFR 
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inhibitors has been explored in clinical trials as potential therapeutic strategies for IBC 
(9). Lapatinib, an EGFR/HER2 dual-kinase inhibitor, was shown to improve clinical 
response in a phase II clinical trial  in combination with paclitaxel in IBC patients (29, 
32). On the otherhand, with about 30-40% of IBC tumors being triple-negative, the 
dual-kinase inhibition of EGFR and HER2 is not likely to be a suitable approach for all 
IBC cases. In fact, one study revealed a HER2-dependency for lapatinib in metastatic 
breast cancer (17, 33). As a consequence of these findings, selective EGFR inhibitors, 
such as erlotinib, have become a major focus for the clinical treatment of IBC. The pre-
clinical studies of selective EGFR inhibitor erlotinib demonstrated suppression of IBC 
tumorigenicity and metastasis, but in a clinical trial erlotinib treatment had a low impact 
on the outcome of advanced breast cancer patients (9, 34). As a result of the 
confounding results for HER2 and EGFR-targeted therapies presented in pre-clinical 
and clinical-based studies, there is still a need to define molecular drivers of IBC 
progression and metastasis.  
1.5 EPITHELIAL TO MESENCHYMAL TRANSITION 
 
A cellular process often associated with breast cancer ‘aggressiveness’ is 
epithelial to mesenchymal transition (EMT). EMT is a reversible process that takes 
place during embryonic development in which cells acquire specific molecular and 
cellular features to facilitate their transition between epithelial and mesenchymal 
phases (35). Following EMT, cells are endowed with mesenchymal properties and a 
migratory phenotype involving the loss of cell-to-cell and cell-matrix adhesion with a 
gain in proteolytic activity. In addition to the loss of cell adhesive properties, there is a 
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remodeling of the cytoskeleton during cellular movement, a critical event for 
gastrulation 
during 
embryonic 
development 
(36). 
Althou
gh EMT is a 
normal 
process 
which 
supports 
embryonic 
development, 
and tissue 
repair, EMT can aberrantly occur in cancer cells in adult breast tissue (35). It is 
proposed that EMT contributes to cancer based on the concordance between the 
mesenchymal phenotype and the characteristics required for cancer cell metastasis. 
Breast cancer cells undergo molecular and cellular changes during EMT that enhance 
cell migratory and invasive capacity, contributing to a metastatic phenotype (35).  
Remarkably, EMT observed in both carcinogenesis and embryonic development is 
mediated by similar signaling pathways (36). EMT cellular changes are orchestrated by 
the release of secreted signals, such as TGF-β and WNTs, from stromal tissues which 
act on nearby epithelial cells (37). These signals mediate the upregulation of 
ILLUSTRATION 1.5 THE INTRINSIC AND EMT-INDUCED CSC WITH 
METASTATIC POTENTIAL 
Cancer stem cells may be intrinsic or induced by extrinsic components, 
such as reactive stromal cells. In the case of an induced phenotype, 
epithelial to mesenchymal transition (EMT) enables the cells to 
transition to a CSC-like phenotype and acquire metastatic potential. 
From ‘A Perspective on Cancer Cell Metastasis’. Christine L. Chaffer 
and Robert A. Weinberg. Science 25 March 2011:331 (6024), 1559-
1564. [DOI:10.1126/science.1203543. Reprinted with permission from 
AAAS. 
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mesenchymal markers, fibronectin and vimentin, N-cadherin, and transcription factors, 
SNAIL, TWIST, SLUG, and ZEB1, in tumor cells. Mesenchymal transcription factors 
suppress the epithelial phenotype and cell-to-cell adhesion through the downregulation 
of epithelial protein E-cadherin (38). The EMT-induced upregulation of mesenchymal 
markers and downregulation of E-cadherin allows cells to acquire an invasive 
phenotype demonstrated in an in vitro 2D culture and three-dimensional (3D) basement 
membrane extract (BME)/Matrigel assay (39) . In addition to the acquisition of an 
invasive phenotype, there is evidence that breast cancer cells, which undergo EMT, are 
endowed with stem cell characteristics (40). EMT can serve as a prerequisite for the 
acquisition of CSC-like traits within a cancer cell subpopulation, resulting in an 
increased metastatic potential of these subpopulation of cancer cells (illustration 1.5).  
It is this subpopulation of cancer cells that must be targeted to block metastasis.  
 
1.6 CANCER STEM-LIKE CELLS 
Cancer stem-like cells (CSCs) are characterized as a subpopulation of cancer 
cells endowed with properties similar to that of normal stem cells such as the ability to 
self-renew, migrate, invade, evade apoptosis, and give rise to a heterogeneous cell 
population which drives recurrence and metastasis (41). Studies imply a role for CSCs 
in the resistance to therapy and progression of breast cancer, but how CSCs contribute 
to these events is not entirely clear (42). The ability to self-renew is a critical feature of 
CSCs and normal stem cells (illustration 1.6) and can be partially demonstrated by an 
in vitro mammosphere assay in which clusters of breast cancer stem cells can 
proliferate and survive under non-adherent non-differentiating culture conditions (43).  
In addition to the mammosphere assay as a surrogate assay for studying the CSC 
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population, several stem 
cell marker studies have 
been conducted to try to 
identify and enrich for 
CSCs in breast cancer 
(44-47). The 
CD44+/CD24- cell 
population was identified 
as a CSC population 
that promotes 
metastasis of breast 
cancer (44). It is well-
established that the 
basal-like subtype of 
breast cancers have derived or have acquired stem cell-like properties during 
transformation (48). Cancer stem cells originating from the basal lineage express cell 
surface molecules such as the hyaluronan receptor CD44 and have downregulated 
heat stable antigen CD24. The expression of CD44 has been linked to the epithelial-to-
mesenchymal transition (EMT) phenotype by which ectopic expression of CD44 in 
normal human mammary cells can facilitate invasion, metastasis, and drug resistance 
(49). From a biological perspective, a single-cell isolation from the cell lineage lin-
/CD24-/CD44+ breast cancer stem cell population can generate new tumors in 
immunocompromised mice, supporting a tumorigenic function of the CD44+CD24- 
subpopulation (13). Although the CD44 and CD24 markers may serve as a positive 
ILLUSTRATION 1.6 THE DIFFERENTIATION OF 
NORMAL AND CANCER STEM CELLS 
In normal tissues, stem cells self-renew and give rise to 
committed progenitor cells which eventually differentiate. 
Progenitor cells have the capability to dedifferentiate under 
the appropriate conditions. In opposition to normal stem 
cells, cancer stem cells have an enhanced ability to 
transdifferentiate from the non-stem cell to stem cell 
phenotype. 
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indicator of stem-like characteristics in some breast tumors, CD44 and CD24 may not 
be expressed in all breast tumors (42).  
In addition to the CD44 and CD24 markers, Aldefluor dehydrogenase 1 (ALDH1) 
is a putative stem cell marker associated with poorly differentiated basal-like breast 
cancers and resistance to therapy (42). As an enzyme that oxidizes intracellular 
aldehydes, it is thought that the activity of ALDH1 may play a role in the early 
differentiation of stem cells (13). The expression of ALDH1 was found to be 
upregulated in several types of carcinomas including malignant breast tissue (13, 50). It 
was also noted as a predictor for metastasis in IBC patients (42). Recently, it was found 
that a rare subpopulation of cells within the CSC population, termed side population or 
SP cells, have the ability to export a fluorescent dye Hoescht  33342 (46). Cells with a 
SP phenotype also have stem cell like characteristics including mammosphere 
formation capability, and the ability to initiate tumor formation in an in vivo mouse 
model. As one particular signaling pathway that promotes breast cancer progression, 
the inhibition of the PI3K/mTOR pathway led to a reduction in the SP cells.  Another 
CSC marker identified as a potential marker for breast cancer stem cells is the 
ganglioside GD2 marker.  Higher expression of GD2 level was observed in the more 
aggressive basal-like breast cancer cells, which included several TNBC cell lines. The 
GD2+ cell population in breast cancer cells demonstrated a CSC phenotype compared 
with GD2- cell population (47). As poorly differentiated breast cancers, IBC and TNBC 
are enriched with CSCs potentially driven by clinically-relevant molecular targets. As 
new evidence emerges supporting the concept of CSCs in the progression of breast 
cancer, there is growing interest in the tumor microenvironment and inflammatory 
signaling pathways and how they regulate breast CSCs. 
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1.7 CYCLOOXYGENASE-2 (COX-2)   
Inflammation plays a critical role in the progression of breast cancer; however, 
the mechanisms are not clearly defined. There is evidence that inflammatory breast 
cancer is associated with inflammatory-like symptoms and activation of inflammatory 
response pathways (51). There are several prospective targets in IBC linked with 
inflammation. As an inflammatory response molecule and transcription factor, NF-
kappa B induces the expression of inflammatory response genes which can facilitate 
breast tumor progression, including the cyclooxygenase-2 (COX-2) gene (52). 
Activation of NF-kappa B is elevated in the basal-like breast cancer subtype which 
includes the EGFR-overexpressing and ER-negative breast cancers (52). In an 
investigation of inflammatory response genes in IBC, one study found that about 60% 
of NF-kappa B-related genes were up-regulated in IBC tumors compared with non-IBC 
tumors (53). Interestingly, PTGS2 (COX-2 gene) was among one of the genes 
upregulated by NF-kappa, which plays a critical role in cell proliferation, angiogenesis, 
and metastasis (53).  
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Unlike COX-1, 
which is constitutively 
expressed in all tissues 
to maintain normal 
tissue homeostasis, 
COX-2 expression is 
undetectable in most 
tissues with the 
exception of immune 
cells, vascular 
endothelium, and 
synovial 
fibroblasts.COX-2 is up-
regulated under 
aberrant conditions 
within tissues displaying inflammation, such as in arthritic joints (54). Upon up-
regulation of its expression and activation by inflammatory cytokines or induction via 
hypoxic conditions (55), COX-2 catalyzes the conversion of arachidonic acid to PGs, 
including its major products, PGE2 and PGF2α (54). In addition to its role in maintaining 
normal tissue homeostasis, PGE2 and PGF2α have a pro-tumorigenic effect in contrast 
to other PGs produced by COX-2 (13). In tumors, where there is a down-regulation of 
the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) which normally 
degrades PGE2 to a 15-keto metabolite, there is an accumulation of the active PGE2 
which leads to a pro-tumorigenic effect (13).  PGE2 contributes to tumor progression 
ILLUSTRATION 1.7 CROSS-TALK BETWEEN EGFR AND 
COX-2 
Stimulation of the EGFR pathway via PGs can activate the 
translocation of ERK1/2 to the nucleus where expression of 
its target genes, including PTGS2, are up-regulated. Erlotini 
or celecoxib can block the overproduction of COX-2 
metabolites, PGE2 and PGF2α, and thereby, inhibit 
EGFR/COX-2-mediated cell proliferation, EMT, invasion and 
CSC phenotype. 
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through binding to the EP4 receptor and the subsequent transactivation of EGFR 
through the Arrestin/Src complex, leading to activation of the PI3K/AKT pathway.  In 
addition, activation of the MAPK/ERK1/2 pathway can occur as a result of PG-
transactivation of the EGFR signaling cascade (13). Cross-talk between EGFR and 
COX-2 leads to an overstimulation in cell proliferation, and promotes EMT, invasion 
and CSC phenotype in breast cancer cells (illustration 1.7).  The link between PGs and 
pro-tumorigenic effects revealed COX-2 as a prospective target for the treatment of 
inflammatory-associated conditions.
 
In early studies, COX-2 inhibitors and non-steroidal anti-inflammatory drugs 
(NSAIDs) were efficacious in the treatment of rheumatoid arthritis through inhibition of 
pain and inflammation.  However, the use of NSAIDs was associated with 
gastrointestinal and cardiovascular side effects (56). To minimize the side effects 
associated with pan-COX inhibition, selective COX-2 inhibitors, celecoxib and 
rofecoxib, were synthesized. These drugs were designed specifically to block the 
enzymatic activity of COX-2 by binding to a site that is accessible in COX-2 but not 
COX-1 in order  to suppress pain and inflammation while minimizing side effects (54). 
In patients with familial adenomatous polyposis (FAP), the use of the first FDA-
approved selective COX-2 inhibitor, celecoxib, reduced the occurrence of sporadic 
colorectal adenomas (57). Although treatment with celecoxib in arthritis and colorectal 
cancer has been successful, the therapeutic efficacy of celecoxib in breast cancer 
remains to be seen.  
Highly invasive and advanced breast cancers including IBC overexpress COX-2 
(58). High COX-2 expression in breast cancer prompted investigation of the correlation 
between COX-2 expression and the CSC phenotype of breast cancer (58). There is 
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evidence that suggests that COX-2 can regulate the CSC phenotype of breast cancer 
cells, however the mechanism remains unknown (59). The overexpression of COX-2 in 
a breast cancer cell line or its transient suppression in a TNBC cell line model showed 
that COX-2 can regulate the EMT phenotype including the expression of genes 
important for motility, invasion, and metastasis (60). COX-2 can mediate the expression 
of MMP-2, a molecule critical for cell motility and invasion, but also those critical for 
tumor immunosuppression such as IL-10 (61, 62). It was recently found that the 
cytokine IL-17 can induce COX-2/PG signaling in cancer cells to indirectly regulate 
tumor-associated macrophages (TAMs) to modulate the microenvironment in favor of 
an immunosuppressive tumor microenvironment (63). Induction of the COX-2/PG 
signaling pathway, via cytokine stimulation, contributes to the progression of breast 
cancer by up regulating the aforementioned PI3K/AKT, MAPK, and NFKB downstream 
targets. Studies using celecoxib revealed a role for COX-2 in the tumorigenicity of IBC 
cells and regulation of breast cancer stem cells (64). By targeting the COX-2 
inflammatory pathway, IBC metastasis could be inhibited through the suppression of 
inflammatory molecules which may regulate the stem cell phenotype, leading to a novel 
treatment strategy for IBC patients (34, 42).              
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1.8 NODAL A STEM CELL 
REGULATOR AND ITS 
ROLE IN BREAST 
CANCER   
It is thought that cancer 
stem cells may arise as a result 
of the uncontrolled expression 
of molecules that control stem 
cell-fate during embryogenesis. 
These embryonic stem cell 
regulators, which are down-
regulated in adult tissues, are 
aberrantly re-expressed in 
tumors.(65).  Nodal, an 
embryonic morphogen and 
regulator of normal mammary 
gland development and stem 
cells, is down-regulated in adult 
tissues but re-expressed in 
malignant breast tumors (65, 66). During embryogenesis, the function of Nodal is to 
direct meso-endoderm formation and the specification of the left-right axis in germ layer 
formation and patterning (67). Nodal is a ligand member of the TGFβ superfamily. The 
canonical signaling of Nodal activates the SMAD2/3/4 signaling pathway through 
binding to an upstream receptor complex CRIPTO/EGF-CFC/Activin-like type I and II 
ILLUSTRATION 1.8 NODAL SIGNALING IN 
BREAST CANCER CELLS 
As a member of the TGFβ superfamily, Nodal 
binds to the heterodimer ALK type I and II 
receptor complex activating SMAD2/3 
transcription factors which complex with SMAD4 
and translocates to the nucleus to induce Nodal 
gene transcription. In the absence of antagonist 
Lefty, breast cancer cells have an up-regulated 
positive feedback loop for Nodal expression.  
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receptors. Upon Nodal binding, SMAD2 is phosphorylated and activated to form a 
complex with SMAD3/4. The SMAD2/3/4 complex translocates to the nucleus where it 
binds with transcription factors, foxh1, Mixer, or P53 to activate the transcription of ld1, 
Nodal, and its inhibitor lefty1/2 (67). The absence of the Nodal antagonist lefty1/2 can 
induce a positive feedback mechanism for the overexpression of Nodal in breast tumor 
cells (illustration 1.8).  
Nodal signaling in breast cancer highly complex due to post-transcriptional and 
post-translational modifications, and potential interactions with other TGFB ligands, 
which can all regulate Nodal signaling (68).  In hypoxia-induced breast cancer 
progression, Nodal expression in breast cancer cells facilitates angiogenesis and 
metastasis (69). Hypoxic or low oxygen conditions can promote the expression of 
Nodal and activation of pro-angiogenic pathways critical to breast tumor progression 
(69). In breast cancer cells, the HIF1-4 transcription factors are induced under low-
oxygen conditions. Through Notch1 stabilization, HIF1 transcription factors are able to 
bind to the NDE promoter site on the Nodal gene to activate the transcription of Nodal. 
However, the interaction between HIF1 and Notch in transcriptional activation of Nodal 
has not been investigated in breast cancer cells (69).  
Another study observed Nodal to promote tumorigenesis and metastasis of 
breast cancer cells via EMT linked to the activation of the MAPK signaling pathway 
(66). This finding suggested that MAPK activation of Nodal via phosphorylation of the 
linker region in SMAD2, promotes SMAD2 activation and subsequent binding to 
SMAD3/4 and translocation to the nucleus for transcription of Nodal. Activation of the 
Nodal signaling pathway can up-regulate mesenchymal markers, down-regulate 
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epithelial markers, and increase cell motility and invasion, which are all prerequisites of 
breast cancer progression and metastasis (66). 
1.9 RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B  
It is known that about 70% of advanced breast cancer patients develop 
metastases and between 65-75% of patients with metastatic breast cancer develop 
bone metastases (70, 71). The occurrence of bone metastasis disrupts normal bone 
remodeling, a tightly regulated balance between osteolytic (bone resorption) and 
osteoblastic (bone formation) activity, causing skeletal-related events and pain (71). 
Uncontrolled regulation of receptor activator of nuclear factor kappa B (RANK), a key 
regulator of normal bone 
remodeling and 
mammary gland 
development, promotes 
metastasis.  
RANK and its 
ligand the receptor 
activator of nuclear 
factor kappa B ligand 
(RANKL) play a major 
role in osteoclast 
differentiation, activation 
and survival. 
RANKL/RANK regulates 
lymphogenesis, and mammary gland development. RANKL binds to its cognate 
ILLUSTRATION 1.9 RANKL/RANK AND THE ‘VICIOUS’ 
CYCLE  
Tumor cells may release cytokines and growth factors that act 
on osteoblasts. The osteoblasts produce RANKL which bind to 
RANK expressed at the surface of osteoclasts and tumor cells. 
Tumor cell proliferation occurs in response to growth factors 
released by osteoclasts. 
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receptor RANK expressed on mammary epithelial cells. Normal mammary gland 
development of lobulo-alveolar structures and lactation morphogenesis are dependent 
upon the function of RANKL/RANK signaling and disruption of this signaling either 
through deletion of RANKL or RANK can lead to underdeveloped mammary glands 
with an inability to secrete milk (72). RANKL expression can be regulated by several 
hormones including parathyroid hormone-related protein (PTHrP) and progesterone.  
During breast cancer progression, it has been demonstrated that RANK-positive cancer 
cells have a higher propensity to metastasize to the bone, an environment enriched 
with pro-tumorigenic RANKL, amongst other growth factors and cytokines that can 
facilitate the formation of metastasis (71).  A model that best describes the tumor- bone 
microenvironment interaction is the ‘vicious cycle’ model. During tumor-bone 
interaction, tumor cells overstimulate the production of RANKL in osteoblasts through 
secreting growth factors and hormones (i.e. PTHrP, and interleukins). The mechanism 
of action for RANKL/RANK is initiated as RANKL binds to RANK expressed on the 
surface of osteoclasts and breast tumor cells. RANKL-induced osteolytic activity 
promotes the proliferation and invasion of tumor cells through the release of tumor-
promoting growth factors, cytokines, and bone matrix components (illustration 1.9) (73-
75).  
Tumor-promoting factors, which promote proliferation and invasion, include 
matrix metalloproteinases (MMPs), bone morphogenetic proteins (BMPs), and tumor 
growth factor β (TGFβ) (71, 74, 76). MMP promoters contain a cis element which can 
be bound by the NFκB transcription factor, a downstream molecule activated by 
RANKL/RANK signaling (77). The matrix metalloproteinase 1 (MMP1) activity induces 
bone matrix degradation as a consequence of bone metastases (78). Under normal 
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conditions, BMPs play a role in osteoblast differentiation and positively regulate bone 
formation. However, as a result of tumor cells invading the bone microenvironment, 
BMPs are able to stimulate the production of pro-osteolytic and osteoblastic factors as 
part of the ‘vicious cycle’ (76). In fact, activated BMPs have also been linked with 
cancer stem cells based upon their regulation of EMT in breast cancer cells (79). As a 
result of RANKL/RANK signaling, another growth factor secreted by osteoclasts and 
tumor cells to stimulate tumor proliferation is TGFβ. TGFβ released by activated 
osteoclasts can directly bind to its receptor expressed on the surface of tumor cells and 
increase production of PTHrP which can act on osteoblasts or stromal cells in 
surrounding visceral tissue to stimulate RANKL production and release. This 
mechanism of action generates a positive-feedback loop that leads to further cancer 
cell growth in bone (80).  
The aggressive phenotype promoted by RANKL is dependent upon RANK 
expression in tumor cells. Indeed, RANK-expressing breast cancer cells were observed 
to undergo EMT (81). Knockdown of RANK expression in an in vivo mouse model had 
reduced the tumorigenesis and self-renewal ability of breast cancer cells indicating a 
potential role for RANK signaling in the regulation of CSCs (82). In line with the 
potential role of RANK in regulating the tumorigenesis and CSC phenotype in breast 
cancer, another study demonstrated that overexpression of RANK increased the 
CD44+CD24- subpopulation and expression of stem cell markers, SOX2, NANOG and 
OCT4 (81).  
In maintaining the physiologic balance between RANKL and RANK in the bone 
matrix, osteoprotegerin (OPG), expressed by osteoblasts, functions as a soluble decoy 
receptor that binds to RANKL, blocking its ability to bind and activate the RANK 
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pathway. In breast tumor cells, there is suppression of OPG expression, resulting in an 
uncontrolled positive feedback loop for RANKL production and activation of the RANK 
pathway (74). As a potential therapeutic strategy to block overstimulated osteolytic 
activity and breast tumor progression, a soluble recombinant form of OPG, OPG-Fc, 
has been studied in breast cancer. OPG-Fc has demonstrated to reduce bone lytic 
disease in breast cancer patients (83). However, due to the potential health risks 
associated with the use of OPG-Fc in humans and its short half-life, a fully-humanized 
antibody, denosumab, was investigated as a potential treatment for targeting RANKL. 
The use of denosumab for osteoporosis treatment has shown efficacy in a phase II 
clinical trial of denosumab treatment in post-menopausal women (84). The proven 
efficacy of denosumab in reducing osteoporosis led to clinical investigations of 
denosumab as a potential therapy for metastatic breast cancer patients.  The use of 
denosumab demonstrated a reduction in SREs and pain-associated with metastatic 
breast cancer in patients (76). More studies are needed to elucidate the mechanism of 
RANK in the metastatic phenotype of TNBC cells and whether targeting the stem cell 
population can inhibit the progression of TNBC. 
1.10 STATEMENT OF PROBLEM 
TNBC and IBC are considered to be the most aggressive and poorly 
characterized breast cancer subtypes. Their high rate of recurrence and metastasis, 
there is an urgent need to identify molecular targets that will help reduce IBC and 
TNBC metastasis and improve clinical outcome (9). There is emerging evidence linking 
CSCs with IBC and TNBC progression. However, it is unknown which molecular 
pathways can be therapeutically exploited to suppress the progression of TNBC and 
IBC. 
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1.11 HYPOTHESIS 
 
We hypothesize that targeted inhibition of COX-2 and RANK in IBC and TNBC, 
respectively, could eradicate CSCs to suppress tumor progression. By targeting COX-2 
and RANK, we can help to eliminate breast cancer metastasis, an inevitable and 
deadly outcome associated with these aggressive diseases. Our findings will advance 
our understanding of how inflammatory mediators, COX-2 and RANK, regulate the 
breast cancer progression and unveil novel potential for COX-2 and RANK as 
therapeutic targets.   
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CHAPTER 2: TARGETING THE RANK PATHWAY AS A 
NOVEL THERAPEUTIC APPROACH IN TNBC 
2.1 INTRODUCTION 
 
Triple-negative breast cancer (TNBC) accounts for approximately 25-30% of all 
breast cancers and is characterized as lacking ER, PR, and HER2 receptors. Although, 
TNBC patients are more likely to respond to neoadjuvant chemotherapy compared with 
non-TNBC patients, metastasis following treatment is more likely to occur in TNBC 
(85). It is thought that breast CSCs contribute to the development of resistance to 
standard therapy and subsequent metastasis (86). Studies demonstrated that the 
RANKL/RANK pathway can regulate the ‘stemness’ of breast cancer cells via EMT, a 
process linked to tumor initiation, progression, and metastasis (81, 82, 87), however, it 
is unclear whether targeted inhibition of the RANKL/RANK pathway could eradicate 
CSCs in TNBC. Since TNBC cells are enriched with stem-like features and 
demonstrate RANKL-stimulated invasion and metastasis, we hypothesized that 
suppressing RANK will eradicate CSCs in TNBC. We investigated RANK in TNBC as a 
potential prognostic marker and predictor for clinical outcome by using statistical 
methods to assess both RANKL and RANK expression in a TNBC patient cohort. In 
addition, we investigated the effects of RANK suppression in TNBC cell migration, 
invasion, and CSC phenotype.  
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2.2 MATERIALS AND METHODS 
 
2.2.1 CDNA MICROARRAY ANALYSIS 
 
We first performed a statistical analysis to compare the gene expression levels 
of RANK between three different patient cohorts derived from the MDACC cohort 
(n=57) of the GEO database: 1) ER+/HER2- (n= 22), 2) HER2+ (n= 17), and 3) ER-
/HER2- (n=18; 17/18 negative for PR). The platform used in which samples were 
constructed on was the Affymetrix U133a GeneChip. Cases with normalized ESR1 
mRNA expression (probe set 205225_at) were defined as ER-positive for ESR1 > 
10.18, cases with HER2 (216836_s_at) were considered HER2 amplified for HER2 > 
12.54, and cases with PgR (208305_at) > 2.907 were considered PR positive (17). The 
probe set for RANK mRNA (TNFRSF11A: 207037_at) was obtained from the ‘gene 
card’ website (http://www.genecards.org/). RANK mRNA expression levels were log2 
transformed and normalized using MAS5 algorithm and the P-values were calculated 
using Wilcoxon test. P > 0.05 was considered to be statistically significant. 
2.2.2 CELL LINES AND TISSUE CULTURE REAGENTS 
 
Human TNBC and non-TNBC cell lines (Table 2.1) were screened for 
endogenous levels of RANK expression. MDA-MB-231, MDA-MB-468, BT20, BT474, 
KPL4 and MCF7 cell lines were maintained in DMEM/F12 Medium (catalog #12634-
010; Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum 
(FBS) (catalog #10438-026; Life Technologies, Grand Island, NY) and 1% antimycotic-
antibiotic (AA) (catalog #15240-062; Life Technologies, Grand Island, NY), and 
SUM149, SUM159 and SUM190 cell lines were maintained in Ham’s F12 Nutrient Mix 
(catalog #11765-054; Life Technologies, Grand Island, NY) 
FBS, 1% AA, 5 µg/mL insulin
µg/mL hydrocortisone (catalog #
atmosphere containing 5% CO
5a (Modified) Medium (catalog #
supplemented with 10% FBS, and 1% AA. 
were maintained in RPMI 1640 
Island, NY) supplemented with 10% FBS and 1% AA.
2.2.3 LENTIVIRAL-BASED EXPRESSION OF 
 
 To generate MDA
produced lentiviral particles from HEK293T cells transfected with the pGIPZ lentiviral 
plasmid expressing short-
TATCTTCTTCATTCCAGCT
a non-silencing sequence 
cells were co-transfected via Lipofectamine (Invitrogen) with lentiviral packaging 
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supplemented with 5% 
 (catalog #I9278; Sigma-Aldrich, St.Louis, MO)
H0888; Sigma-Aldrich, St. Louis, MO
2 at 37°C. SKBR3 cell line was maintained in McCoy’s 
16600-082; Life Technologies, Grand Is
HCC70, HCC38, and HCC1954 cell lines 
medium (catalog #11875-119; Life Technologies, Grand 
 
RANK SHRNA 
-MB-231 cells with stable knockdown of RANK protein, we 
hairpin RNA (shRNA) against RANK (mature anti
- 5’; mature sense 5’- ATAGAAGAAGTAAGGTCGA
(scrambled shRNA) (GE Healthcare, Dharmacon). 
, and 1 
) in a humidified 
land, NY) 
 
-sense 3’-
-3’) or 
HEK293T 
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vectors DR82, and VSV-G along with the target plasmid (pGIPZ-Scrambled shRNA or 
pGIPZ-RANK shRNA). MDA-MB-231 cells were seeded at 5 x 104 cells/well into a 24-
well plate 24h prior to infection with lentiviral infected medium. A 5-fold serial dilution 
(dilution factors of 5, 25, 125, 625, 3125, 15625) of viral particles diluted 1/10 in serum-
free media were used to infect the 231 cells at 5 x 104 cells/well in a 24-well plate and 
293T cells were infected in parallel as a control. At 6 hours post-infection, 1 mL of 
complete media was added per well. Cells were cultured for 48h prior to observing GFP 
expression seen by light microscope.  
 GFP-positive colonies were counted and the transducing unit per milliliter 
(TU/mL) or multiplicity of infection (MOI) was calculated using the following formula: 
(average number of GFP-positive colonies calculated for 4 wells) x (dilution factor) x 
40. The lowest MOI was 0.17 for the 125-fold dilution factor. The MDA-MB-231 cells 
infected at the lowest MOI were treated with selection antibiotic puromycin (1 µg/mL) 
and expanded in culture. Following selection for 2 weeks in 1 ug/mL puromycin diluted 
in complete media, the MDA-MB-231 cells infected with pGIPZ-Scrambled shRNA, or 
RANK shRNA, were screened for RANK protein expression via flow cytometry analysis. 
2.2.4 FLOW CYTOMETRY ANALYSIS 
 
To analyze the level of RANK in MDA-MB-231 Scrambled shRNA and MDA-MB-
231 RANK shRNA cells, we stained for the following: DAPI (cell viability), APC + IgG1 
(negative control), RANK (APC + N2-B10) (Table 2.2).  MDA-MB-231 parental cells 
were stained as a control only. 
 Cells were blocked in FACS blocking 
+ PBS) for 20 minutes at 4°C with rotatio
103 rpm. Cells were re-suspended in FACS buffer (2% fetal bovine serum + 0.005% 
sodium azide + PBS) with primary RANK antibody (N2
isotype antibody and incubated under the same conditions as in the blocking step. 
Cells were washed 2X with FACS buffer prior to incubation with the secondary antibody 
(APC) for 30 minutes. For the final wash step, cells were washed 2X with FACS buffer 
prior to re-suspension in 1 mL FACS buffer
instrument (MDACC Flow Cytometry Core Facility). 
FlowJo_V10 software (figure 1).
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buffer (3-5% goat serum + 0.005% sodium azide 
n then spun down at 4°C for 4 minutes a
-B10) or purified mouse IgG
, and analyzed using Gallios flow cytometry 
Histograms were generated using 
 
t 4 x 
1 
28 
 
2.2.5 CELL MIGRATION AND INVASION ASSAYS 
 
MDA-MB-231 scrambled shRNA and RANK shRNA cells were serum starved for 
24 hours prior to stimulation with 25 ng/mL human soluble RANKL (product #R138; 
Leinco Technologies, Inc. St. Louis, MO) for 24 hours. For Boyden chamber trans-well 
migration assay (n=3), 1.5 × 105 cells in serum-free medium were layered in the top 
chamber of 24-well trans-well plates with serum-free media containing RANKL (25 
ng/mL) in the lower chamber and incubated at 37°C for 6 hours. Cells in the top 
chamber (non-migrated) were removed, and cells in the bottom chamber (migrated) 
were fixed with 0.1% crystal violet/20% methanol solution. For the invasion assay 
(n=3), 1.5 × 105 cells were plated in serum-free medium in the upper chamber of a 
Boyden chamber coated with BD Matrigel Basement Membrane Matrix Growth Factor 
Reduced Phenol Red Free (catalog #356231; BD Biosciences) with serum-free media 
containing RANKL (25 ng/mL) in the lower chamber. Twenty-four hours later, non-
invading cells were removed from the upper chamber, and the underside membranes 
were fixed and stained as above in the cell migration assay. Migrated and invaded cells 
were quantitated by dissolving stained cells in a solution of 4% sodium deoxycholate 
and performing colorimetric reading of optical density at 595 nm. Results were 
analyzed using unpaired Student’s t-test with a *P value < 0.05 considered significant. 
2.2.6 MAMMOSPHERE ASSAY 
 
MDA-MB-231 scrambled shRNA and RANK shRNA cells were plated into an 
ultra-low attachment 6-well plate at a density of 5 × 103 cells/well containing 
Mammocult Basal Medium (catalog #05621; STEMCELL Technologies, Inc.) 
supplemented with 1% Proliferation Supplement (catalog #5622; STEMCELL 
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Technologies, Inc.), 2 µg/mL heparin (catalog #07980; STEMCELL Technologies, Inc.), 
and 0.12 µg/mL hydrocortisone (catalog #07904; STEMCELL Technologies, Inc.). On 
day 5 following incubation, cells from primary mammospheres (P0) were counted and 
re-plated for secondary mammosphere (P1) formation. Under both primary and 
secondary mammosphere conditions, each group was tested in triplicate. 
Mammospheres were quantitated on day 5 by staining with MTT reagent (0.4 mg/mL) 
for 2 hours and enumerated using GelCount software (Oxford Optronix). Results were 
analyzed using unpaired Student’s t-test with a *P value < 0.05 considered statistically 
significant.  
2.2.7 HUMAN STEM CELL RT2 PCR ARRAY ANALYSIS 
 
Using the human stem cell RT2 PCR array (catalog #PAHS405Z; Qiagen) we 
analyzed the gene expression levels of several stem cell markers in MDA-MB-231 
scrambled shRNA and RANK shRNA cells. We purified total RNA from each cell line 
using the RNeasy Mini prep kit (catalog #74104; Qiagen). The total RNA samples were 
reverse transcribed to cDNA using the RT2 First-strand Kit (catalog #330401; Qiagen), 
followed by mixing of the synthesized cDNA with the RT2 SYBR Green Mastermix 
(catalog #330513; Qiagen) then samples were aliquoted (25 µL/well) into the human 
stem cell PCR array 96-well assay plate. The 96-well assay plate included 84 wells 
containing primers specific for 84 genes of interest (GOI) and the remaining 12 wells 
were control wells including 5 wells for housekeeping genes, 3 wells for reverse-
transcription controls, and 1 well for control DNA genomic contamination, and 3 wells 
for positive PCR controls (Table 2.3). 
The 96-well plate reactions were generated 
96 model) with cycling conditions compatible with
2.4) 
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using a real-time PCR cycler (Bio
 the Bio-Rad CFX96 cycler (
-Rad CFX 
Table 
The results were analyzed using the C
PCR data array analysis Web Portal. The C
as < 35 or > 35 in which the < 35 values were reported as negative. 
CT value for each gene of interest (GOI) 
following formula was used:
2.2.8 CORRELATIVE ANALYSIS 
CLINICAL OUTCOME IN TNBC
 
We performed an analysis to correlate 
overall survival and time to first metastases in TNBC patients. C
from formalin-fixed paraffin
constructed on TMAs (88)
RANK (N-1H8 or N2-B10; Amgen, Inc., Seattle, WA) and RANKL
Seattle, WA) monoclonal antibodies 
by pathologist D.B. blinded to
RANK and RANKL 
score) formula defined as 
(percentage of 0 intensity )
intensity) * 2 + (percentage of 3
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T method available through the SABiosciences 
T value for each reaction was 
to the average housekeeping
 CT = CT GOI – CT AVG HKG. 
OF RANK, RANKL, AND ALDH1 EXPRESSION 
 
the expression of human 
ore samples
-embedded (FFPE) MDACC TNBC patient tumors 
 and stained by immunohistochemistry (IHC) 
 (M366; Amgen, Inc., 
as described in (89), and interpreted and scored 
 clinical characteristics and outcome. 
expression was quantitated based on the histoscore (
the sum of intensity  (0, 1, 2, 3) x percentage of intensity; 
 * 0+ (percentage of 1 intensity) * 1 + (percentage of 2 
 intensity) * 3. H scores range from 
 
determined 
To normalize the 
 genes the 
WITH 
RANK with 
 (n = 96) 
were 
with anti-human 
H 
0-300 where 
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intensity of staining was defined as 0 = negative, 1 = weak, 2 = moderate, 3 = high, 
relative to RANK staining in tumor-associated macrophages as an internal control. 
Using the median (RANK H score = 10) as the cut-off value, RANK IHC staining 
results were categorically defined as: high RANK (H score > or = 10) or low RANK (H 
score < 10), and clinicopathological parameters: age (median = 50 years), race, tumor 
size, lymph nodes, pathological stage (pStage), nuclear grade (NG), and 
lymphovascular invasion (LVI), were tabulated and compared between the high RANK 
and low RANK groups using the Fisher’s exact test; P < 0.05 statistically significant. 
The Kaplan-Meier survival curve analysis was used to estimate the survival of each 
group: high RANK (n = 49) and low RANK (n= 47) and were compared using a log-rank 
test; P < 0.05 statistically significant. SPSS statistic software (version 20.00; IBM 
corporation, Armonk, NY) was used to estimate the association between each RANK 
group and ‘Overall survival ‘defined as from date of surgery to date of death or loss of 
follow-up and ‘Time to first metastases’ defined as from date of surgery to date of first 
metastases detected.  The median follow-up time was 2025 days (range 346-5906).  
TNBC patient tumors (n=91) were stratified as RANK positive (RANK >0; n=66) 
or RANK negative (RANK =0; n=25). A correlative analysis was performed for RANKL 
expression with clinicopathological parameters (appendix D) and statistically analyzed 
using fisher’s exact test, P-value > 0.05 considered to be significant. Kaplan-Meier 
curves for OS and RFS was performed for both RANK positive and RANK negative 
cohorts, and a log-rank test was performed to determine the p-value. SPSS statistic 
software (version 20.00; IBM corporation, Armonk, NY) was used to estimate the 
association between RANKL > 0 and RANKL = 0 in both RANK cohorts.  
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IHC staining of ALDH1 was performed on proximal TMA sections of TNBC tumor 
specimens (MDACC Histology Core Facility) as described in (42) and interpreted and 
scored by pathologist S.K. blinded to clinical characteristics and outcome. ALDH1 
scores were determined based on the average percentage of intensity in either tumor 
cells and/or stroma.  
2.2.9 STATISTICAL ANALYSIS FOR CLINICAL AND NON-CLINICAL DATA 
 
Patients with histologically defined TNBC were divided into two groups based on 
H scores: RANK positive (H score > 0) and RANK negative group (H score =0). 
Baseline patients’ characteristics include age, race, menopausal status, pathological 
stage, nuclear grade, lymphovascular invasion, and estrogen receptor expression and 
they were tabulated. For the comparison of continuous variables, we used Wilcoxon 
rank sum test. Associations between two groups were assessed by using Fisher’s 
exact test. Overall Survival (OS) was defined from the date of surgery to that of death 
and Recurrence Free Survival (RFS) was defined from the date of surgery to that of 
first local or distant metastasis or lost follow-up whichever comes earlier. Patients who 
died before having a recurrence event were censored at the date of death. The Kaplan-
Meier survival curves were used to estimate the survival of each group and two groups 
were compared by using log-rank test. Chi-square test or Fisher’s exact test was used 
to assess the correlation among categorical variables depending on their expected 
values. Multivariate Cox proportional hazard models were used to evaluate the 
association of covariates with survival.  Covariates with p-value < 0.3 in univariate 
analysis were included in multivariate analysis. 
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A p-value < 0.05 was considered statistically significant. All statistical analyses 
were performed by STATA version 13 (STATA Corp, College Station, TX). This study 
was approved by the Internal Review Board at the University of Texas MD Anderson 
Cancer Center.  
For cDNA microarray analysis, cases were normalized with MAS5 algorithm and 
RANK mRNA gene expression was log2 converted and the P-value was calculated by 
the wilcoxon test.   For all other in vitro studies, student t-test was performed to 
determine the p-value. P-value > 0.05 considered significant.  
For all other data, results were presented as mean ± SD except where otherwise 
stated. When two groups were compared, Student’s t-test was used (P < 0.05 was 
considered significant).  
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2.3 RESULTS 
 
2.3.1 RANK IS HIGHLY EXPRESSED IN HUMAN TNBC PRIMARY TUMORS 
 
Since the study of RANK expression in breast tumors has resulted in 
discrepancies in RANK expression in breast tumors and  its prognostic value, and has 
not yet been studied in TN breast tumors (90), we evaluated the clinical relevance of 
RANK expression in TNBC by first interrogating the expression of RANK and RANKL 
amongst TNBC patients. We analyzed the level of RANK mRNA expression in patient 
tumors from the MDACC IBC data set. ER-/HER2- (n=18) was compared with other 
breast cancer cohorts, ER+/HER2- (n=22) and HER2+ (n=17) by statistical analysis of 
patient tumor-derived RANK mRNA constructed on an Affymetrix U133a GeneChip 
array. We found the ER-/HER2- cohort to have a statistically significant higher level of 
RANK expression compared to the ER+/HER2- breast tumor cohort (P = 0.034) while 
there was not a statistically significant difference in RANK mRNA expression between 
ER+/HER2- and HER2+ cohorts (Figure 2.1). In addition, we looked at RANK mRNA 
expression in TNBC and non-TNBC primary tumors and observed RANK mRNA levels 
to be higher in the TNBC compared to non-TNBC tumors (Figure 2.2). 
 
 
 
 
 
 
Figure 2.1 RANK mRNA 
tumors than ER+/HER2
Affymetrix U133a GeneChip array
following cohorts: ER-/HER2
Results were normalized with MAS5 algo
calculated by Wilcoxon test (P
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expression is significantly higher in ER
- tumors. We analyzed RANK gene expression using an 
 containing mRNA from breast tumors taken from the 
- (n= 18) cohort, HER2+ (n=17), and ER+/HER2
rithm and log2 transformed and p
-value = 0.034). 
 
-/HER2- breast 
- (n=22). 
-values were 
  
 
 
 
 
 
 
 
Figure 2.2 RANK mRNA 
non-TNBC tumors. We analyzed RANK gene expression using an Affymetrix U133a 
GeneChip array containing mRNA from breast tumors
cohorts: TNBC (n=17) and non
algorithm and log2 transformed and p
= 0.045). 
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expression is significantly higher in TNBC compared to 
 (n=57) taken from the following 
-TNBC (n=40). Results were normalized with MAS5 
-values were calculated by Wilcoxon test (P-value 
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2.3.2 RANKL IS A PREDICTOR OF WORSE CLINICAL OUTCOME IN RANK-POSITIVE TNBC 
 
Previous retrospective studies have shown that RANK expression can predict 
the occurrence of skeletal-related events (SREs), bone disease progression, and death 
(75). As effective RANK signaling requires the presence of RANKL, we sought to find 
out if associated RANK and RANKL expression in TNBC tumors could better delineate 
clinical outcome. TMAs constructed with core biopsies from TNBC patients (n=91) and 
tumor-associated macrophages (TAMs) were stained as an internal control for RANK 
and RANKL positivity (data not shown) with anti-human RANK monoclonal antibody (N-
1H8 or N2-B10; Amgen, Inc.) and RANKL antibody (M366; Amgen, Inc.). RANK and 
RANKL expression was semi-quantitated by H score method. The cut-off value for 
positive RANKL/RANK was H score > 0. Based upon our initial analysis that a 
univariate analysis of RANK expression did not correlate with clinicopathological 
parameters and was not associated with a lower RFS or OS (data not shown), we 
performed statistical analyses for RANKL expression in both RANK negative and 
RANK positive cohorts. According to a Fisher’s exact test (P –value > 0.05 significant) 
to correlate clinicopathological parameters (age, race, menopause, NG, pStage, and 
LVI) in the whole cohort (n=91) (Table 2.5), 55.4% (n=41) of RANKL-negative TNBC 
patients correlated with pStage II disease (p-value = 0.551; not significant). There was 
a significant correlation between nuclear grade III and RANKL negativity, 94.6% (n=69) 
of RANKL negative tumors were nuclear grade III (p-value < 0.01). Lymphovascular 
invasion did not significantly correlate with RANKL expression (p-value = 0.705). In a 
univariate and multivariate analysis for 5-year recurrence and overall survival in the 
RANK positive TNBC cohort (n=66), RANKL expression was found to be an 
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independent predictor for worse survival outcome (Table 2.6). A Kaplan-Meier survival 
curve analysis was performed to determine if RANKL associated with a poorer relapse-
free survival and overall survival. We did not observe RANKL associated with survival 
outcome in RANK negative cohort (Figure 2.3), but we did observe RANKL associated 
with a worse survival outcome (Figure 2.4). 
 
 
 
 
 
 
 
40 
 
 
 
Figure 2.3 RANKL expression is not associated with 
analysis of TNBC patients with primary breast tumors negative for RANK expression
16) or negative (n=74) was performed for re
performed between RANKL positive and negative groups in each analysis 
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poor clinical outcome in RANK-negative TNBC
 (RANK = 0) including
currence-free survival (left), and for overall survival (right
to determine the p-value.  
 
. Kaplan-Meier curve 
 RANKL positive (n= 
). A log-rank test was 
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Figure 2.4 RANKL expression is associated with 
TNBC patients with primary breast tumors positive fo
(n=55) was performed for assessment of recurrence
between RANKL positive and negative groups to determine the p
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poor clinical outcome in RANK-positive TNBC. 
r RANK expression (n=66) were stratified as RANKL positive
-free survival (left) and overall survival (right). A log
-value. 
 
Kaplan-Meier curve analysis of 
 (n=11) or negative 
-rank test was performed 
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2.3.3 HUMAN TNBC CELL LINES HAVE HIGHER EXPRESSION OF RANK THAN NON-TNBC 
CELL LINES 
 
Based on our clinical findings that RANK expression was higher in the TNBC 
cohort compared to non-TNBC, we screened a panel of human TNBC and non-TNBC 
cell lines for RANK protein expression by flow cytometry analysis. By immunostaining 
of endogenous RANK with an anti-human RANK monoclonal antibody (N2-B10) and 
APC secondary antibody, followed by detection using flow cytometry analysis, we 
observed higher APC-RANK expression levels in the majority of TNBC cell lines 
compared to non-TNBC cell lines (Figure 2.5). We calculated the median difference 
between the isotype control peak (red) and APC-RANK peak (blue). We found the 
TNBC cell lines to have a higher median difference and averaged median difference 
compared to the non-TNBC cell lines (Appendices A and B). The MDA-MB-231 TNBC 
cell line had high levels of RANK expression that was comparable to that of other 
TNBC cell lines (HCC70, MDA-MB-468, and HCC38). Due to its high tumorigenicity 
and metastatic ability, we used the MDA-MB-231 cell line for subsequent experiments 
to investigate the role of RANK in TNBC cells. We investigated the effects of RANK 
suppression in MDA-MB231 to characterize the role of RANK and determine if RANK is 
a potential therapeutic target for inhibiting the progression of TNBC.
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Figure 2.5 RANK expression is higher in TNBC cell lines compared to non-TNBC 
cell lines. A panel of human A) TNBC and B) non-TNBC cell lines were screened by 
flow cytometry for endogenous RANK expression. Isotype control (red peak), and APC-
RANK positive (blue peak). Y-axis = Count (number of cells); X-axis = APC-RANK 
signal intensity. Flow cytometry results were analyzed by FlowJo version VX software. 
The APC positive value medians for TNBC and non-TNBC were calculated and 
graphed using Graphpad Prism version 6.01 (boxplot graph). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
2.3.4 SUPPRESSION OF RANK DECREASED MDA-MB-231 CELL MIGRATION AND 
INVASION  
 
Evidence suggests RANK/RANKL to promote breast cancer metastasis, but the 
role of RANKL/RANK in breast cancer metastasis is not well understood. Using MDA-
MB-231 cells, we investigated the effects of RANK suppression in TNBC cell migration 
and invasion. In consensus with another study conducted by Tang ZN et al. (91), after 
we observed suppression of RANK to have little effect on the migration and invasion of 
MDA-MB-231 cells in the absence of RANKL-stimulation (data not shown), we pre-
stimulated MDA-MB-231 scrambled shRNA and RANK shRNA cells with 25 ng/mL 
human soluble RANKL for 24 hours prior to seeding cells for 6-hour Boyden chamber 
transwell cell migration and 24-hour cell invasion assay. We observed MDA-MB-231 
RANK shRNA cells to have significantly decreased cell migration (figure 2.6A) and 
invasion (figure 2.6B).   
 
 
 
 
 
 
 
 Figure 2.6 Suppression of RANK 
migration and invasion. 
shRNA cells were pre-stimulated with
prior to a Boyden chamber transwell cell 
hour). A) Cells migrated for 6 hours, B) cells invaded growth factor
24 hours. Migrated and invaded cells were quantitated by fixing and staining with 0.1% 
crystal violet/20% methanol solution followed by resuspension in 4% sodium 
deoxycholate and quantification using Perkin
0.01 statistically significant.
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reduced RANKL-stimulated MDA
MDA-MB-231 scrambled shRNA and MDA
 human soluble RANKL (25 ng/mL) 
migration (6-hour) and invasion assay
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-Elmer Microplate reader at 595 nm. 
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-MB-231 RANK 
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 (24-
Matrigel for 
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2.3.5 SUPPRESSION OF RANK DECREASED SELF-RENEWAL ABILITY 
 
The RANKL/RANK pathway plays an important role in the progression of breast 
cancer, but the CSC phenotype which contributes to the invasiveness of TNBC, had 
not been well-studied (91).To determine if RANK can regulate the CSC phenotype, we 
performed a mammosphere assay in which MDA-MB-231 RANK shRNA, or MDA-MB-
231 Scrambled shRNA cells were cultured under low adherence conditions in 
mammosphere media. Following a 6-day incubation period, we observed a reduction in 
the number of primary mammospheres (P0) formed and the number of secondary 
mammospheres (P1) formed which is associated with a reduction in the self-renewal 
ability of MDA-MB-231 cells (Figure 2.7).  
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.7 Mammosphere formation 
was reduced by the suppression of RANK
MDA-MB-231 RANK shRNA 
in mammosphere media and cultured for 6 days 
formation followed by re-plating of cells 
(self-renewal ability) for an additional 6 days
with 5 mg/mL MTT reagent 
statistically significant. 
 
 
 
 
 
50 
 
and self-renewal ability of MDA
. MDA-MB-231 scrambled shRNA and 
cells were seeded into ultra-low attachment 
for primary (P
for secondary (P1) mammosphere formation 
. P0  and P1 mammospheres were stained
for 1 hour then quantitated by GelCount software
 
-MB-231 cells 
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. *P < 0.01 
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2.3.6 STEM CELL GENES ARE MODULATED BY THE SUPPRESSION OF RANK IN MDA-MB-
231 CELLS  
 
Previous studies have found that the RANKL/RANK pathway regulates EMT and 
CSC phenotype of breast cancer cells (81, 92). To determine which stem cell pathways 
are regulated by RANK in TNBC cells, we analyzed stem cell gene expression levels of 
MDA-MB-231 RANK shRNA cells using a human stem cell RT2 PCR array. We 
observed several stem cell genes downregulated in MDA-MB-231 RANK shRNA cells 
when normalized to the MDA-MB-231 scrambled shRNA cells (Figure 2.8). The top five 
stem cells genes that had the greatest reduction in expression based on the fold-
regulation were: 1) BMP2, 2) CCND2, 3) FOXA2, 4) SOX2, and 5) BMP3 (Table 2.3).  
Figure 2.8 Human stem cell genes in MDA-MB
PAHS405A) was used to analyze stem cell gene expression in MDA
shRNA. A heat map was generated showing the log 2 fold
normalized to MDA-MB-231 scrambled shRNA. 
fold-regulation and the top 5 stem cell genes of interest 
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-231 cells are modulated by the suppression of RANK
-MB-231 RANK shRNA normalized to MDA
-change in stem cell gene expression for MDA
The negative inverse of the fold-change (data not shown) was 
were selected based on the greatest magnitude of 
 
. A qRT PCR array (Qiagen 
-MB-231 Scrambled 
-MB-231 RANK shRNA 
calculated to obtain the 
fold-regulation (Table 2.3).  
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2.4 DISCUSSION 
 
TNBC is one of the most aggressive and deadliest breast cancer subtypes 
without any clinically-defined molecular targets for treatment. There is a critical need for 
finding a therapeutic target to prevent the relapse and progression of TNBC. 
RANKL/RANK pathway is critical to the metastasis of breast cancer. Although RANK 
expression is associated with increased metastasis and poor prognosis in breast 
cancer, RANK has not been investigated in the progression of TNBC. In determining 
whether RANK expression is associated with the more aggressive TNBC subtype, we 
analyzed the basal levels of RANK gene expression in primary breast tumors 
constructed on an Affymetrix cDNA GeneChip array. Stratified by hormone receptor 
status, our results indicated RANK expression to be higher in the ER-/HER2- breast 
tumors compared to ER+/HER2- breast tumors (Figure 2.1). Despite the significantly 
higher RANK gene expression in the ER-/HER2- breast tumors compared to 
ER+/HER2- breast tumors, ER-/HER2- breast tumors did not have significantly higher 
level of RANK expression compared to the HER2+ breast tumors. When we had 
analyzed RANK expression in breast tumors stratified as TNBC or non-TNBC, we 
found RANK expression was significantly higher in TNBC tumors (Figure 2.2). This 
finding is in concordance with another study conducted by Santini D. et al. in which ER- 
breast tumors were found to have significantly higher RANK expression compared to 
hormone receptor-positive breast tumors (93). Thus, this finding suggests RANK 
expression to be elevated in TNBC tumors compared to non-TNBC tumors, and 
provides a rationale to investigate RANK protein expression and its prognostic value in 
TNBC patient tumors.  
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Generally, the more aggressive breast cancer subtypes are associated with a 
poorer prognosis. To investigate whether RANKL or RANK expression in TNBC 
associated with a poorer clinical outcome, we analyzed IHC staining of RANK and 
RANKL proteins in TNBC TMAs. In the whole cohort of TNBC patients (n=91), we 
performed a correlative analysis to look at RANKL expression and clinicopathological 
parameters. We found a significant correlation between RANKL negative tumors and 
nuclear grade (NG) III clinical factor (Table 2.1). This suggests that in the absence of 
RANK expression (n=25), RANKL does not predict an advanced and poorly 
differentiated TNBC tumor. In a Kaplan-Meier curve analyses for RANK negative cohort 
stratified by RANKL, we observed RANKL did not have an association with the 
recurrence-free survival or overall survival in TNBC patients (Figure 2.3). This finding 
supports the results of our initial analysis that RANK expression alone, irrespective of 
RANKL, is not a predictor of clinical outcome in TNBC patients (data not shown). 
Alternatively, we analyzed RANKL expression in the RANK positive cohort (n= 66) 
performing univariate and multivariate analyses using clinicopathological parameters 
that were obtainable for up to 5 years post-diagnosis. In both analyses, we observed 
RANKL positive tumors to be associated with a worse 5-year recurrence and overall 
survival compared to RANKL negative tumors (Table 2.2). This suggests RANKL to be 
an independent predictive factor for the 5-year recurrence and overall survival in TNBC 
patients. In the Kaplan-Meier curve analysis for recurrence-free survival and overall 
survival, we observed an association between RANKL positive and a shorter 
recurrence-free survival and overall survival (Figure 2.4). In relation to other studies 
which have indicated RANK to be associated with a poor breast cancer prognosis (94), 
our results indicate RANK expression to be essential for the RANKL association with 
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poor prognosis of TNBC. In contrast to our study, Santini D. et al. reported low 
expression of RANK in primary breast tumors and concluded RANK to be a predictive 
marker for bone metastasis in breast cancer patients (93). The discordance between 
our study and the study by Santini D. et al. of RANK expression associated with overall 
survival could be explained by the different methods used to define the cut-off for 
RANK expression, and the variability in IHC staining of RANK protein, which can result 
in detected RANK-positive events in tumor samples across both studies. Owen S. et al. 
observed a breast cancer cohort with reduced RANK mRNA expression to have a 
significantly poorer overall survival compared to those with higher RANK mRNA 
expression (95). In contrast to this, an investigational study of RANK protein in primary 
breast tumors found RANK did not correlate with clinical factors while high RANK 
expression associated with a poorer outcome compared to low RANK expression (94). 
In addition, Park et al. observed RANK protein expression to associate with a poorer 
disease-free survival and RANKL to significantly correlate with primary breast tumors 
with a lower Ki67 proliferative index (96). In comparison, we also did not observe RANK 
to correlate with clinical factors but did find RANKL negativity to correlate with a higher 
nuclear grade. We speculate that depending upon the breast tumor cohort, RANK is 
associated with a poorer clinical outcome and RANKL is a predictive factor for a 
clinically aggressive TN breast tumor in the presence of RANK. This could indicate that 
activated RANKL/RANK pathway promotes an aggressive TNBC phenotype and poorer 
outcome.  
Upon observing an association between the co-expression of RANK and RANKL 
and poorer outcome in TNBC patients, we investigated whether endogenous RANK 
expression in a TNBC cell line can recapitulate an aggressive behavior in in vitro 
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studies. We performed flow cytometry analysis to compare endogenous RANK protein 
levels between a panel of TNBC and non-TNBC cell lines. Endogenous RANK protein 
expression was observed to be higher in TNBC cell lines compared to non-TNBC cell 
lines (Figure 2.5). Interestingly, the TNBC cell line SUM149 was observed to have a 
lower amount of RANK protein expression relative to the other TNBC cell lines. Within 
the non-TNBC cohort, ER-/HER2+ cell lines SUM190, SKBR3, and HCC1954, were 
observed to have relatively higher amount of RANK protein level compared to all other 
non-TNBC ER+ cell lines. These results confirm that ER- breast cancer tends to have 
higher levels of RANK expression compared to ER+ breast cancers. However, there is 
a general consensus that there is discordance in RANK expression in breast tumors 
and breast cancer cell lines at the transcriptional and protein level (90, 91). TNBC is a 
heterogeneous disease and that RANK expression varies across breast cancer 
subtypes as we had observed that not all TNBC cell lines have high RANK expression. 
Possible reasons for discordance between the reported RANK expression level in cell 
lines may be due to the variation in post-transcriptional regulatory mechanisms and 
immunohistochemistry staining for RANK protein (74). Nevertheless, our findings 
warrant a comparative study of RANK expression between TNBC molecular subtypes 
(BL1, BL2, IM, LAR, M, MSL, and UNS). By applying this strategy, we may be able to 
determine if RANK expression in TNBC tumors or cell lines is significantly associated 
with a particular TNBC molecular subtype.  
To study the biological role of RANK in the invasive and CSC phenotype of 
TNBC cells, we knocked down RANK in MDA-MB-231 using a lentiviral-based shRNA 
system. We observed the suppression of RANK, following stimulation with and in the 
presence of RANKL as a chemo attractant, to significantly reduce MDA-MB-231 cell 
57 
 
migration and invasion. This result is comparable to what was observed in other studies 
of RANKL-stimulated MDA-MB-231 cell migration and invasion (91, 97). Jones D.H. et 
al. reported RANKL-independent signaling through CXCR4 chemokine signaling 
pathway in MDA-MB-231 cell migration and invasion (97). CXCR4 chemokine receptor 
expression is upregulated by the NFkB pathway. Tang Z. et al. reported the inhibition of 
Src to abrogate RANKL-stimulated MDA-MB-231 cell migration and invasion, and 
concomitantly suppressed downstream activity of ERK1/2, P38, and JNK (91). Other 
studies have shown that these same pathways were activated following RANKL 
stimulation in ER-negative and ER-positive breast cancer cell lines, SKBR3 and T47D, 
respectively (82, 97). Although our in vitro migration and invasion assays confirmed the 
suppression of RANK significantly reduced RANKL-stimulated TNBC cell migration and 
invasion, we do not know which signaling pathways downstream of RANK mediate 
MDA-MB-231 cell migration and invasion. Further studies are required to investigate 
potential signaling pathways downstream of RANK, including JNK, P38 MAPK, and the 
activation of NFκB, as mediators of TNBC cell migration and invasion. 
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Since CSCs are 
associated with breast 
cancer cell motility and 
invasion and are 
features of an 
aggressive phenotype, 
we investigated 
whether the 
suppression of RANK 
negatively regulates 
the self-renewal ability 
of TNBC cells by 
performing an in vitro 
mammosphere assay. 
In the mammosphere 
assay, we observed the knockdown of RANK to significantly reduce primary and 
secondary MDA-MB-231 mammospheres. Thus, we concluded RANK to positively 
regulate the CSC phenotype of TNBC cells. Our findings are in concordance with other 
studies, which demonstrated RANK regulation of breast CSCs in TNBC cells. It was 
observed in a study by Pelligrini P. et al. that overexpression of RANK promoted the 
repopulation of differentiated breast tumor cells and cancer stem cells in an in vivo 
mouse model (98).  
To find out if the suppression of RANK modulated stem cell genes in MDA-MB-
231 cells, we performed a RT2 PCR human stem cell array analysis to compare the 
ILLUSTRATION 2.4 A PROPOSED MODEL FOR 
RANKL/RANK-MEDIATED BMP2 SIGNALING IN TNBC 
CELLS 
RANKL binds to RANK expressed on the surface of TNBC 
cells  and induces  the transcription of BMP2 which then the 
secreted form binds to its receptor to activate the SMAD1/5/8 
signaling cascade to activate transcription of several pro-
metastatic and inflammatory genes such as other BMPs, 
MMPs, and IL-11. This chain of events supports a proliferative 
and pro-metastatic state including EMT and CSC phenotype. 
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expression levels of stem cell genes between MDA-MB-231 RANK shRNA and MDA-
MB-231 Scrambled shRNA cells. Based on our findings, we concluded RANK regulates 
breast CSCs through stem cell genes implicated in cell proliferation and differentiation. 
Bone morphogenetic protein 2 (BMP2) had the greatest magnitude in fold-regulation (-
22.91), followed by CCND2 (-16.28), FOXA2 (-13.55), SOX2 (-11.17) and BMP3 (-8.72). 
The bone morphogenetic proteins (BMPs) are growth factors which regulate cell 
proliferation and differentiation. BMP2 in particular is considered a mesenchymal stem 
cell-specific marker which regulates cell differentiation (12), while BMP3 is an 
antagonist for the BMP receptor (99). FOXA2 and SOX2 are both stem cell regulators 
involved in cancer metastasis. CCND2 (cyclin D2), a proliferative marker and regulator 
for G1/S phase cell cycle transition, can increase malignancy through enrichment of the 
stem cell population (100). However, there is no evidence suggesting that RANKL 
stimulation of RANK in breast tumor cells regulates the expression of cyclin D2. As 
opposed to BMP3, which has anti-tumorigenic effects, BMP2 harbors oncogenic activity 
to promote tumor cell invasion and metastasis. In a study by Blake M.L. et al., RANKL 
stimulation of MDA-MB-231-RANK cells up-regulated pro-metastatic genes MMPs 
(MMP1, 3, 7, and 9) and IL-11 (55). In addition, another study found metastatic genes 
up-regulated in a bone-metastatic derivative subpopulation of MDA-MB-231 cells (101). 
Transcription factors FOXA2 and SOX2 play a critical role in regulating progenitor cell 
development, differentiation, and migration (102). The link between SOX2 and breast 
cancer progression is that it’s found to be primarily expressed in early-stage breast 
cancers rather than in the later-staged or invasive breast cancers, indicative of a 
functional role in tumor initiation (103). The mechanism underlying the dedifferentiation 
of breast cancer cells by SOX2 expression is unknown, however, one study indicated 
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NFkB to indirectly regulate SOX2 (103). NFkB is a target downstream of the 
RANKL/RANK pathway and therefore, it is logical to conclude that the stem cell genes 
in the PCR array screen are possibly indirectly modified by the suppression of RANK. 
In addition, the methods used to investigate gene expression regulated by RANK, 
including stimulation with or without RANKL stimulation, are likely to vary the outcomes 
in expression of these stem cell genes. Therefore, our study warrants an investigation 
into the modification of stem cell genes (BMP2, BMP3, SOX2, FOXA2, and CCND2) by 
RANKL stimulation.  
In summary, the observation of higher RANK expression in TNBC tumor 
samples merits an investigation into the prognostic value of the RANK pathway in a 
clinical cohort of TNBC. Our findings suggest that there is a positive correlation 
between RANK and RANKL protein expression which  is associated with poor 
prognosis of TNBC patients.  Based on in vitro studies, we conclude that targeting the 
RANK pathway could be a potential strategy for reducing the progression of TNBC. We 
will investigate molecular pathways downstream of RANK, including regulators of the 
stem cell phenotype to elucidate the mechanism of TNBC progression through RANKL 
stimulation. We will perform experimental and spontaneous metastasis mouse models 
using a TNBC cell line expressing luciferase-tagged RANK shRNA in mice, we will 
generate experimental and spontaneous metastasis models to monitor the effects of 
RANK suppression on TNBC metastasis and expression of metastatic and stem cell 
markers.     
From a clinical perspective, targeting RANKL to block RANKL/RANK activity in 
TNBC is a suitable approach because there is evidence of improved breast cancer 
patient survival and reduced bone metastases following denosumab treatment.   A 
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Phase II Clinical study in ER-positive breast cancer patients, in which denosumab has 
already been described to reduce bone metastases, we will investigate the effects of 
denosumab on the presence of CTCs and DTCs. Since the use of denosumab has not 
been studied in a TNBC patient population, we may also conduct a pilot study in TNBC 
patients treated with neoadjuvant denosumab in which the presence of CTCs and 
DTCs will be evaluated before and after denosumab treatment.    
CHAPTER 3: COX-2 PROMOTES TUMORIGENESIS OF IBC 
THROUGH THE REGULATION OF NODAL   
3.1 INTRODUCTION 
 
IBC is one of the most aggressive breast cancers accounting for approximately 
8-10% of all breast cancer-related deaths in the U.S. Despite the fact that IBC is a 
locally advanced breast cancer associated with inflammatory-like symptoms, a 
physiologic mechanism of inflammatory response has not yet been found in IBC. There 
is evidence that implicates a role or COX-2 in enrichment of CSCs in breast cancer. 
However, the mechanism of COX-2-regulated breast CSCs is not clearly defined. 
Suppression of the CSC phenotype in IBC may have anti-tumorigenic and anti-
metastatic potential. It was reported in IBC that the EGFR pathway promotes EMT, a 
requisite of breast cancer metastasis and an observed invasive-like phenotype 
associated with CSCs. In this study, we not only observed a positive correlation 
between EGFR and COX-2 expression in IBC tumors, but we found COX-2 to regulate 
EMT in IBC cells. Furthermore, in our investigation, treatment with COX-2 selective 
inhibitor, celecoxib, downregulated Nodal expression, a potential stem cell marker 
regulated by COX-2. Thus, we evaluated the Nodal stem cell pathway as a potential 
target for eradicating CSCs in IBC.   
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3.2 MATERIALS AND METHODS 
 
3.2.1 CDNA MICROARRAY ANALYSIS  
 
For this study, we used an Affymetrix U133a GeneChip array constructed with 
cDNA derived from human IBC (n = 25) and non-IBC (n = 57) tumor specimens from 
The University of Texas MD Anderson Cancer Center IBC database. Gene expression 
obtained from the microarrays was normalized with the MAS5 algorithm, mean-
centered to 600 and log 2-transformed. Statistical analyses were performed by using 
BRB-ArrayTools version 3.9.0 alpha (http://linus.nci.nih.gov/BRB-ArrayTools.html) and 
R statistical software version 3.0.0 (http://www.r-project.org/). The correlation between 
the mRNA expression levels of EGFR (211551_at) and COX-2 (204748_at) was 
analyzed using the Spearman’s rank correlation coefficient analysis. 
3.2.2 CELL LINES AND TISSUE CULTURE REAGENTS 
 
Human non-IBC breast cancer cell lines, BT-474, SK-BR-3, MDA-MB-231, 
purchased from American Type Culture Collection, were grown in Dulbecco’s modified 
Eagle’s medium/F12 medium supplemented with 10% FBS (GIBCO/BRL) in a 
humidified atmosphere containing 5% CO2 at 37°C. IBC cell lines, SUM149 and 
SUM190, were purchased from Asterand (Detroit, MI) and were grown in Ham’s F12 
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medium supplemented with 5% FBS, 5 µg/mL insulin, 1 µg/mL hydrocortisone, and 1% 
antibiotic-antimycotic. The human IBC cell line KPL-4 (104) was kindly provided by Dr. 
Junichi Kurebayashi (Kawasaki Medical School, Japan) and maintained in Dulbecco’s 
modified Eagle’s medium/F12 medium supplemented with 10% FBS and 1% antibiotic-
antimycotic. Non-IBC and IBC human breast cancer cell lines were validated using a 
short term tandem repeat method based on a primer extension to detect single base 
derivations in October 2010, and July 2013, respectively, by the Characterized Cell 
Line Core Facility at M.D. Anderson Cancer Center. Cells used for experiments were 
grown in culture for no longer than 2 months. All cell lines were confirmed to be 
mycoplasma free using a MycoAlert Mycoplasma Detection Kit (Lonza Cologne AG). 
For prostaglandin (PG) treatment, cells were serum-starved for 24 hours prior to adding 
PGE2 (catalog #14010; Cayman Chemical) or PGF2α (catalog #16010; Cayman 
Chemical) was added to the cells cultured in serum-free medium. Celecoxib (Selleck 
Chemicals, Houston, TX) was reconstituted in dimethyl sulfoxide (DMSO). 
Recombinant human Nodal (R&D Systems, Inc., Minneapolis, MN) was reconstituted in 
4 mM HCl and 0.1% bovine serum albumin solution. 
3.2.3 WESTERN BLOT ANALYSIS 
 
Cell lysates were prepared as follows: 1) Cells were washed 1X with cold 1X 
PBS, 2) On ice, 1 mL of cold 1X PBS was added/plate or well and cells were scraped 
with a cell lifter and collected in 1.5 mL Eppendorf tubes, 3) cells were centrifuged for 4 
minutes at 4°C at 4 x 103 rpm, 4) cell pellets were lysed on ice in 30-40 uL 1X RIPA cell 
lysis buffer containing 1:100 phosphatase and protease inhibitors, and finally, cell 
lysates were cleared by centrifugation for 30 minutes at 4°C at maximum speed (13.2 x 
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103 rpm). See ‘Bradford Protein Assay’ methods section for determination of total 
protein concentrations. 
Western blot analysis was performed as previously described (105) using the 
following antibodies (table 3). anti-EGFR (catalog # sc-03; Santa Cruz Biotechnology, 
Inc.), anti-Phospho-EGFR (Y1173) (catalog #sc-12351; Santa Cruz Biotechnology), 
anti-COX-2 (catalog #160112; Cayman Chemical), anti-E-cadherin (catalog #610182; 
BD Biosciences), anti-fibronectin (catalog # 610077; BD Biosciences), anti-vimentin 
(catalog #AB-1620; Chemicon International), anti-N-cadherin (catalog #4061S; Cell 
Signaling), and anti-β-actin (catalog #A-5441; Sigma-Aldrich). 
3.2.4 SIRNA TRANSFECTION 
 
Using Invitrogen Oligofectamine 2000 reagent (catalog # 12252-001), SUM149 
cells were transfected with COX-2 or EGFR-targeted siRNA. The COX-2 siRNA 
oligonucleotide sequences # 1 (forward 5’GAAUCAUUCACCAGGCAAA-3’ and reverse 
5’-UUUGCCUGGUGAAUGAUUC-3’) and #2 (forward 5’- 
CUCCAAACACAGUGCACUA-3’ and reverse 5’-UAGUGCACUGUGUUUGGAG-3’) 
were transfected into SUM-149 cells at 200 nM final concentration per well. Into a 6-
well plate containing 3 x 105 SUM149 cells/well. At the 4h time point, complete medium 
was added at 1 mL/well. At 48h post-transfection, cells were harvested and lysed with 
1:10 dilution of 10X RIPA cell lysis buffer  (125 mL 1M Tris-HCL PH 7.4, 25 mL NP-40, 
12.5 mL SDS, 5 mL 0.5 M EDTA, 12.5 g NaDOC, 75 mL 5M NaCl2 , and 7.5 mL 
distilled H2O). 
3.2.5 PROSTAGLANDIN EXTRACTION AND ANALYSIS  
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Endogenous PGE2 and PGF2α were extracted from IBC and non-IBC cells, and 
PG levels were analyzed by using quantitative high-performance liquid chromatography 
tandem mass spectrometry (HPLC-MS/MS) according to the protocol of Yang et al. (3). 
Briefly, cell pellets were suspended in 0.5 mL of PBS, 40 µL of 1 N citric acid, and 5 µL 
of 10% (w/v) butylated hydroxytoluene. PGs were extracted by liquid-liquid extraction 
using 2 mL of 1/1 ethyl acetate/hexanes (v/v), three times. The organic layers were 
separated, pooled, and evaporated to dryness under nitrogen. The samples were 
reconstituted in 100 µL of 50/50 methanol/0.1% acetic acid (v/v). Prostaglandins were 
detected using an Agilent 6460 triple quadrupole mass spectrometer (Agilent 
Technologies, Palo Alto, CA) equipped with an Agilent HP 1200 binary HPLC pump. 
PGE2 and PGF2α were separated using a 2 × 100-mm Kinetex 3 µm C18 analytical 
column (Phenomenex, Torrance, CA). Mobile phase A consisted of 0.1% formic acid, 
and mobile phase B was acetonitrile with 0.1% formic acid. Compounds were eluted 
with a gradient starting at 20% B and ramped to 90% B over 14 minutes. The column 
temperature was maintained at 40°C, and samples were kept at 4°C during the 
analysis. For the detection and quantification of PGE2 and PGF2α  levels in SUM149 
xenograft tumors from mice, following tumor extraction the tissue samples were 
processed and reconstituted prior to analysis by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) as follows in Pirman D.A. et al (55). 
 
  
3.2.6 QRT2PCR 
 
Total RNA was extracted using the RNeasy Mini kit (Qiagen). Real-time 
quantitative RT-PCR was performed using the Bio-Rad iScript One-Step RT-PCR kit. 
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7S rRNA was used as a housekeeping gene. The relative quantitation value for each 
target gene compared to the calibrator for that target was expressed as 2-(Ct-Cc) (Ct and 
Cc are the mean threshold cycle differences after normalization to 7SL rRNA). 7SL 
primers were as follows: forward 5’-ATCGGGTGTCCGCACTAAGTT-3’; reverse 5’-
CAGCACGGGAGTTTTGACCT-3’. 
The relative expression levels of samples were presented using a semi log plot. The 
sequences of the primers used in this study were as follows: E-cadherin: forward 5’-
AGTGCCAACTGGACCATTCA-3’, reverse 5’-TCTTTGACCACCGCTCTCCT-3’; N-
cadherin: forward 5’-ACTCGCAGACGCTCACACGC-3’, reverse 5’-
GCGGGACTCGCACCAGGAGT-3’; fibronectin: forward 5’-
CCATCACTGTGTATGCTGTC-3’, reverse 5’-TGGTTTGTCAATTTCTGTTCGG-3’; 
Snail: forward 5’-TCCAGGCTCGAAAGGCCTTCAAC-3’, reverse 5’-
GCAGCGTGTGGCTTCGGATGT-3’; Slug: forward 5’-GGGTGACTTCAGAGGCGCCG-
3’, reverse 5’-GGCGGTCCCTACAGCATCGC-3’; vimentin: forward 5’-
CAAGGGCCAAGGCAAGTCGCG-3’, reverse 5’-ACGCGGGCTTTGTCGTTGGTTA-3’; 
and Nodal forward 5’-AGCATGGTTTTGGAGGTGAC-3’, reverse 5’-
CCTGCGAGAGGTTGGAGTAG-3’. 
3.2.7 FLOW CYTOMETRY ANALYSIS 
 
For the detection of CSC markers, SUM149 cells were collected by 
trypsinization and stained with anti-CD44 and anti-CD24 antibodies and analyzed by 
multicolor flow cytometry. Briefly, combinations of fluorochrome-conjugated monoclonal 
antibodies against human CD44 (fluorescein isothiocyanate; catalog #555478; BD 
Biosciences) and CD24 (phycoerythrin; catalog #555428; BD Biosciences) or their 
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respective isotype controls were added to the cell suspension at concentrations 
recommended by the manufacturer and incubated at room temperature in the dark for 
30 minutes. The labeled cells were washed and resuspended in FACS buffer (PBS + 
1% FBS) and then analyzed on a FACSVantage flow cytometry system (BD 
Biosciences). Cell populations with high aldehyde dehydrogenase (ALDH) enzymatic 
activity were identified using an ALDEFLUOR fluorescent reagent system according to 
the manufacturer’s method (STEMCELL Technologies Inc., Vancouver, Canada). 
Briefly, 1 × 106 SUM149 cells were collected following trypsinization, and 2.5 × 105 cells 
were resuspended in Aldefluor assay buffer containing ALDH substrate. As a negative 
control, we used di-ethylaminobenzaldehyde, a potent inhibitor of ALDH activity. Cells 
were then incubated at 37°C for 30 minutes with Aldefluor, washed with Aldefluor assay 
buffer, and stained with 1 µg/mL propidium iodide (Sigma) to discriminate viable cells 
from dead cells before detection in the green fluorescence channel (520-540 nm) on 
the flow cytometer (Beckman Coulter Gallios Instrument). 
 
 
3.2.8 CELL MIGRATION AND INVASION ASSAYS 
 
MDA-MB-231 scrambled shRNA and RANK shRNA cells were serum starved for 
24 hours prior to stimulation with 25 ng/mL human soluble RANKL (product #R138; 
Leinco Technologies, Inc. St. Louis, MO) for 24 hours. For Boyden chamber trans-well 
migration assay (n=3), 1.5 × 105 cells in serum-free medium were layered in the top 
chamber of 24-well trans-well plates with serum-free media containing RANKL (25 
ng/mL) in the lower chamber and incubated at 37°C for 6 hours. Cells in the top 
chamber (non-migrated) were removed, and cells in the bottom chamber (migrated) 
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were fixed with 0.1% crystal violet/20% methanol solution. For the invasion assay 
(n=3), 1.5 × 105 cells were plated in serum-free medium in the upper chamber of a 
Boyden chamber coated with BD Basement Membrane Matrigel Growth Factor 
Reduced Phenol Red Free with serum-free media containing RANKL (25 ng/mL) in the 
lower chamber. Twenty-four hours later, non-invading cells were removed from the 
upper chamber, and the underside membranes were fixed and stained as above in the 
cell migration assay. Migrated and invaded cells were quantitated by dissolving stained 
cells in a solution of 4% sodium deoxycholate and performing colorimetric reading of 
optical density at 595 nm. Results were analyzed using unpaired Student’s t-test with a 
*P value < 0.05 considered significant. 
3.2.9 MAMMOSPHERE ASSAY 
 
SUM149 or KPL-4 cells were plated into a 6-well plate at a density of 3 × 105 
cells/well and pretreated for 24 hours with 10, 25, or 50 µM celecoxib. As a control, 
cells were pretreated with DMSO. For generation of primary mammospheres, SUM149 
cells were seeded at 2 × 104 cells/well or KPL-4 cells were seeded at 2.5 × 103 
cells/well into an ultra-low-attachment 6-well plate containing Mammocult Basal 
Medium (catalog #05621; STEMCELL Technologies, Inc.) supplemented with 1% 
Proliferation Supplement (catalog# 05621; STEMCELL Technologies, Inc.), 2 µg/mL 
Heparin (catalog #07980; STEMCELL Technologies, Inc.), and 0.12 µg/mL 
hydrocortisone (catalog #07904; STEMCELL Technologies, Inc.) with celecoxib or 
DMSO. On day 5, primary mammospheres were passaged to secondary 
mammospheres. Both primary and secondary mammosphere conditions were tested in 
triplicate. Mammospheres were quantitated on day 5 by staining with MTT reagent (0.4 
mg/mL) for 2 hours and enumerated using GelCount software (Oxford Optronix). 
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Results were analyzed using unpaired Student’s t-test with a P value < 0.05 being 
considered significant. 
3.2.10 THREE-DIMENSIONAL (3D) MATRIGEL ASSAY 
 
As a surrogate model for the invasive-like epithelial-to-mesenchymal (EMT) 
phenotype, the three-dimensional (3D) Matrigel assay was created to allow for the 
assessment of the ‘invasiveness’ of cells in a basement layer-like substrate. During the 
migratory process of breast cancer cells, the cells must invade the surrounding stroma 
which encapsulates the luminal and basal layers of the mammary tissue. The cells 
ability to transverse the basal layer is represented in the cells’ ability to invade the 
basement membrane and help organize communication between cells embedded 
within the matrix as in the 3D-Matrigel assay. Matrigel is an enriched substance 
composed of key growth factors found in the basement membrane of tissue including 
factors found in the extracellular membrane (ECM) (106). The Matrigel used was 
derived from Engelbreth-Holm-Swarm (EHS) mouse sarcoma and contained the 
components laminin, collagen IV, heparin sulfate proteoglycans, and entactin/nidogen. 
Corning Basement Membrane Matrix (catalog #356234; BD Biosciences) was thawed 
on ice, and a bottom layer consisting of 65 µL of Matrigel solution was added per well 
into a four-well chamber slide (Lab-Tek II; Nalge Nunc International, Rochester, NY) 
then incubated at 37°C for 30 minutes to allow for solidification. Then 5 × 104 cells were 
resuspended in 500 µL of culture medium supplemented with 2% Matrigel on ice and 
added to the solidified bottom layer. At 24-hours post-incubation at 37C, images of the 
cell projections were captured and tube formation (invasive structures) was quantitated 
using S.CORE (S.CO LifeSciences GmbH, Munich, Germany) or Wimasis (GmbH, 
Munich, Germany) analysis software.  
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3.2.11 IBC XENOGRAFT MODEL 
 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC protocol 02-03-02134) of MD Anderson Cancer Center. A total 
volume of 0.15 mL of SUM149 cell suspension containing 2 × 106 cells with 50% 
Matrigel was injected into the fourth inguinal mammary gland of 8-week old female 
nu/nu mice. The mice were fed ad libitum with a regular diet for 3 weeks, at which time 
the tumors were well established. The mice were then randomly allocated (n=8 per 
group) to control diet (regular food pellets) or to one of two treatment diets, 250 ppm or 
500 ppm celecoxib, for the following 5 weeks. Mice were weighed and estimated to be 
about 25 g/mouse and food intake per mouse was estimated to be about 3 g/day. The 
diet dose was calculated based on the formula: diet dose (DD) = Single daily dose (SD) 
x body weight (BW) x daily food intake (FI) (www.researchdiets.com/resource-
center/diet-dose-calculator.com; Research Diets, Inc. New Brunswick, NJ). The 250 
and 500 ppm (mg/kg of mouse body weight/day) diet dose translated to approximately 
2083 mg of celecoxib/kg BW, and approximately 4167 mg of celecoxib/kg BW, 
respectively. Tumor volumes were determined by calculating weekly caliper 
measurements using the following formula: tumor volume (V) = (L × W2) × 0.5, where L 
is the length and W is the width of the tumor. Tumor growth inhibition (%) was 
calculated as 1 - (tumor volume change of treatment group / tumor volume change of 
control group) × 100%. 
3.2.12 STATISTICAL ANALYSIS 
 
Data are presented as mean ± SD except where otherwise stated. When two groups 
were compared, Student’s t-test was used (P < 0.05 was considered significant).  
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3.3 RESULTS 
 
 3.3.1 IN VITRO TARGETING OF COX-2 AND EGFR IN IBC CELLS  
 
We proposed EGFR to regulate the expression of COX-2 in IBC cells since we 
initially found a positive correlation between EGFR and COX-2 expression levels in IBC 
tumor samples (Figure 3.1). In determining if this correlation existed in IBC cell lines at 
the protein level, we immunoblotted for COX-2, and activated EGFR in IBC and non-
IBC cell lines. We observed the IBC cell line SUM149 to co-express both COX-2 and 
activated EGFR (Figure 3.2). We observed EGF stimulation to increase COX-2 protein 
expression in SUM149 cells (Figure 3.3), and EGFR-targeted siRNA to suppress COX-
2 expression (Figure 3.4). In addition, we observed erlotinib treatment in SUM149 cells 
to decrease COX-2 expression (Figure 3.5). The occurrence of decreased COX-2 
levels subsequent to suppressed EGFR expression and activity indicated that EGFR 
positively regulates COX-2 expression in SUM149 cells. This finding supports our 
hypothesis that EGFR positively regulates COX-2 in IBC cells. As previous findings 
suggested that COX-2-activated expression is regulated through the EGFR pathway 
(34), we investigated the levels of PGs to assess COX activity following treatment with 
celecoxib and erlotinib and vehicle-treated SUM149 cells at 24h and 48h time points 
(Figure 3.6). Basal levels of PGs (PGE2 and PGF2α) were checked in a panel of IBC 
and non-IBC cell lines (Figure 3.7), in which we found PGs to be higher in the IBC cell 
lines compared to the non-IBC cell lines. Collectively, these findings suggest EGFR to 
regulate the expression and activity of COX-2 in IBC cells and that pharmacological 
intervention with COX-2 or EGFR-targeted therapy may reduce the tumorigenicity of 
IBC cells as observed by the downregulation of PGE2, the most tumorigenic byproduct 
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of COX-2 activity. In determining whether COX-2 plays a functional role in the 
tumorigenicity and progression of IBC cells, we investigated the biological function of 
COX-2 in in vitro studies and an in vivo study.  
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Figure 3.1 EGFR correlates with COX-2 gene expression in breast cancer. We 
correlated EGFR and COX-2 gene expression in IBC (n=25) and non-IBC (n=57) tumor 
samples constructed on an Affymetrix cDNA microarray. The correlative analysis was 
performed using the Spearman’s Rank Correlation Coefficient analysis. IBC data (P-
value = 0.01; rho = 0.51); non-IBC data (P-value = 0.04; rho = 0.269).  
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 Figure 3.2 COX-2 and EGFR expression in IBC 
SDS-PAGE was performed using total protein lysate samples collected from IBC and 
non-IBC cell lines cultured under normal conditions. A western blot was performed to 
immunoblot for basal level expression of 
IBC cell lines. Β-actin was 
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and non-IBC cell lines.
COX-2, EGFR, and p-EGFR in 
used as a loading control.  
 
 
IBC and non-
 Figure 3.3 EGF stimulates 
SUM149 cells were serum
free medium for the time points as indicated (15, 30, or 60 minutes
Ctl; untreated control. COX
actin was used as a loading control. Odyssey imager was used to detect the protein.
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COX-2 expression in SUM149 cells. 
-starved then stimulated with 0.1 µg/mL 
 and 4 or 24
-2, EGFR, and p-EGFR proteins were immunoblotted. 
 
of EGF in serum-
 hours). 
Β-
 
 Figure 3.4 Suppression of 
SUM149 cells. SUM149 cells were
siRNAs, negative siRNA, or not transfected as a control
and lysing cells to collect and isolate total protein lysate. A total of 30 µg of protein was 
loaded/well for SDS-PAGE on a 8% resolving gel and transferred to a PVDF 
membrane. The membrane was immunoblotted 
total EGFR, and COX-2. 
were probed with AlexaFluor (680 nm) secondary antibody.
scanned using the LI-COR imager. 
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EGFR expression reduced COX-
 transiently transfected with pooled EGFR
 for 48 hours prior to harvesting 
with primary antibodies fo
β-actin was immunoblotted as a loading control. Samples 
 The membrane was 
NT; non-transfected, neg; negative, and si; siRNA
 
 
 
 
 
 
 
2 expression in 
-targeted 
r pEGFR, 
.  
 Figure 3.5 Erlotinib reduced 
SUM149 cells were treated with EGFR
and 72 hours prior to immunoblotting for 
untreated control. 
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COX-2 levels in SUM149 cells.  
-specific tyrosine kinase inhibitor, erlotinib, for 48 
COX-2 and β-actin as a loading control
 
 
. Ctl; 
Figure 3.6 Celecoxib and 
cells. SUM149 cells were treated with celecoxib (10 µM), erlotinib (0.5 µM), or DMSO 
(control) for 48 hours prior to 
contained 3 x 106 cells/mL 
(measured from cells collected at 48 hours post
(measured from media collected at 48 hours post
PGF2α levels were calculated as ng/mL/
GraphPad Prism version 6.01 
78 
 
 
erlotinib reduced PGE2 and PGF2α levels in SUM149 
collecting cells and cell media for analysis
of 1X PBS for HPLC/MS analysis of insoluble PGE
-treatment) and soluble PGF
-treatment)
. 
Quantitated PG
106 cells and results were graphed using 
software. 
 
 
 
 
 
. Each sample 
2 
2α 
E2 and 
Figure 3.7 IBC cell lines have higher levels of COX activity compared to non
cell lines. Under normal culture conditions, a
lines were analyzed for soluble
HPLC/MS analysis. Quantitated soluble PGE
PGF2α (% relative to SUM149) were graphed using 
6.01software.  
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 panel of human IBC and non
 PGE2 and PGF2α levels at 1 x 106 cells/mL of 1X PBS 
2 concentrations (ng/mL/10
GraphPad 
 
-IBC 
-IBC cell 
by 
6
 cells) and 
Prism version 
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3.3.2 COX-2 REGULATES IBC CELL MIGRATION AND INVASION 
 
Previous studies have found COX-2 to regulate the tumorigenicity and 
invasiveness of breast cancer cells, however, the mechanism by which COX-2 
promotes IBC tumorigenicity and invasiveness has not been well studied in IBC (58, 
64). PGE2 is known to have tumorigenic effects, and to promote a stem cell-like 
phenotype, however, this link remains to be elucidated in IBC. In finding out whether 
the COX-2 pathway is required for IBC cell migration and invasion, we performed a cell 
migration and invasion assay using SUM149 cells. Cells were serum-starved for 24 
hours prior to stimulation with 0.5 µM PGE2 or PGF2α or untreated as a control for 24 
hours. We observed SUM149 cell migration and invasion significantly increased by 
PGs (Figure 3.8), while celecoxib decreased SUM149 cell migration and invasion 
(Figure 3.9).  
 
 
 
 
 
Figure 3.8 Prostaglandin stimulation increased SUM149 cell migration and 
invasion. SUM149 cells were serum
a control or treated with PGE
seeded at 2.5 x 105 cells/well in which cells were incubated with serum
containing PG or without PG (untreated) for 
24-hour cell invasion assay
crystal violet/20% methanol solution for 5 minutes 
were counted and averaged per well
version 6.01 software. *P= 0.002; **
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-starved for 24 hours then either left untreated as 
2 or PGF2α (0.5 µM) in triplicate for 24 hours
A) 6-hour cell migration 
 (n=3). Migrated and invaded cells were stained 
and under a light microscope cells 
. Results were graphed using GraphPad Prism 
P < 0.0001. 
 
 
 
 
 
 
 
. Cells were 
-free media 
assay (n=3) or B) 
with 0.1% 
Figure 3.9 Celecoxib inhi
SUM149 cells were pre-treated with 50 µM of celecoxib 
hours prior to seeding at a density of 2.5 x 10
assay (n=3), or B) 24-hour 
stained with 0.1% crystal violet/20% methanol solution for 5 minutes then dissociated 
from the membrane by incubation with 4% sodium deoxycholate for 20 minutes. 
Samples were quantitated by 
microlabel plate reader. Results were graphed using GraphPad Prism version 6.01 
software.  *P < 0.01. 
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bited the migration and invasion of SUM149 cells.
or untreated 
5 cells/well for A) 6-hour cell migration 
cell invasion assay (n=3). Migrated and invaded cells were 
luminescence (595 nm) using Perkin
 
 
in triplicate for 24 
-Elmer Victor X 
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3.3.3 THE EMT AND CANCER STEM-LIKE CELL PHENOTYPE IN IBC CELLS IS REGULATED 
BY THE COX-2 PATHWAY 
 
The reversible process of EMT allows cells to acquire molecular features such 
as upregulation of mesenchymal markers Fibronectin, Vimentin, N-cadherin, and 
transcription factor Twist, and downregulation of epithelial marker E-cadherin. Whether 
through PG stimulation or treatment with a selective COX-2 inhibitor, the COX-2 
pathway is shown to play a role in EMT in breast cancer cells. The link between the 
COX-2 pathway, EMT and stem-like properties has not been elucidated in IBC cells. To 
investigate whether the COX-2 pathway regulates EMT and stem-like properties in IBC 
cells, we treated SUM149 cells with PGs (0.5 µM) or celecoxib (10 or 25 µM) and 
immunoblotted for EMT markers. We observed PGs to down-regulate E-cadherin, while 
up-regulate mesenchymal markers, Fibronectin, Vimentin, and Twist (Figure 3.10 left 
panel). In celecoxib-treated SUM149 cells, E-cadherin was up-regulated, while 
mesenchymal markers, Fibronectin, Vimentin, and N-cadherin were down-regulated 
(Figure 3.10 right panel). In addition, we observed celecoxib-treated SUM149 and KPL-
4 IBC cells to demonstrate a reduction in projection formation in 3D matrigel culture 
(Figure 3.11). PG-stimulation increased the CSC population, CD44+/CD24- 
subpopulation, in SUM149 cells (Figure 3.12). Aldefluor (ALDH1) activity in SUM149 
cells were increased by PGs, but decreased by celecoxib (Figure 3.13). The formation 
of SUM149 primary and secondary mammospheres  was decreased by celecoxib 
(Figure 3.14). 
 
 
 
 Figure 3.10 The expression of EMT markers are regulated by 
SUM149 cells. SUM149 cells were stimulated with PGE
unstimulated as a control (Ctl) 
hour starvation and lysate was i
cells were treated with vehicle control (0), or celecoxib (10 or 25 µM) for 48 hours and 
cell lysate was immunoblotted for EMT markers 
immunoblotted as a loading control. 
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COX
2 or PGF
for 72 hours under serum-free conditions 
mmunoblotted for EMT markers (left panel). SUM149 
(right panel)
 
 
-2 activity in 
2α (0.5 µM) or 
following a 24 
. Β-actin was 
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Figure 3.11 Celecoxib suppressed the EMT-like phenotype in 3D Matrigel culture. 
SUM149 cells and KPL-4 cells were treated with celecoxib (2, 10, and 50 µM) or 
untreated (0) in triplicate for 24 hours in 2D culture and under Matrigel culture 
conditions for another 24 hours. Images of the projections or tube formations (not 
shown) were taken using a light microscope connected to a Nixon camera. Projections 
were quantitated and averaged by S.Core for SUM149 EMT assay and Wimasis for 
KPL-4 EMT assay. Using GraphPad Prism version 6.01 software, results were 
calculated as a percentage of projections formed relative to untreated cells.  
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CD44+CD24- cell population in SUM149 
2 or PGF2α (0.5 µM) for 24 hours prior to 
-CD24 antibodies. Untreated control SUM149 cells 
- subpopulation, while PGE2 and PGF2α stimulated SUM149 
on of 66.7% and 66.5%, respectively.
 
 
Figure 3.13 COX-2 increased the 
were stimulated with PGE
by flow cytometry after treatment
celecoxib for 4 days and detected for 
**P = 0.0003 (right panel). 
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Aldefluor activity of SUM149 cells. 
2 or PGF2α for 6 days and the aldefluor activity was detected 
. *P = 0.0109; **P = 0.0016 (left panel), or treated with 
Aldefluor activity by flow cytometry
 
 
SUM149 cells 
, *P = 0.0013; 
Figure 3.14 Celecoxib reduced 
were plated at a density of 3 x 10
or celecoxib (10 µM) (n=3) 
attachment plate. Live cells dissociated from primary (
with trypan blue solution and counted using the Cellometer prior to re
culturing for secondary (P
mg/mL MTT reagent and enumerated
software. *P < 0.005. 
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SUM149 mammosphere formation
4 cells/well and treated with DMSO as a control
for 5 days under mammosphere conditions in a low
P0) mammospheres were stained 
1) mammospheres.    Mammospheres were
 after 5 days using GelCount plate reader and 
 
. SUM149 cells 
 (n=3) 
-
-plating and 
 stained with 5 
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3.3.4 THE TUMORIGENICITY OF IBC IS SUPPRESSED BY CELECOXIB 
 
 The aggressiveness of IBC is likely due  to the stem cell-like phenotype which 
promotes tumorigenicity (64). As observed with other breast cancer subtypes, COX-2 
activity has tumorigenic effects, which can be inhibited by the selective COX-2 inhibitor 
celecoxib. In a previous study, we had observed erlotinib, an EGFR inhibitor, to 
suppress IBC tumorigenicity and metastasis (34). To determine whether celecoxib has 
anti-tumorigenic effects in an IBC xenograft mouse model, we treated an orthotopic 
SUM149 xenograft mouse model with celecoxib. We investigated the effects of 
celecoxib on IBC tumorigenicity by the measurement of tumor growth and the levels of 
PGE2 and PGF2α in the tumors. We observed celecoxib treatment to significantly reduce 
tumor growth compared to control (untreated) mice (Figure 3.15). In addition, we found 
PG levels to be lower in tumors derived from celecoxib-treated mice compared to 
control mice (Figure 3.16). Since EMT is a stem cell-like characteristic associated with 
the invasiveness and CSC population in breast cancer, we analyzed the expression of 
epithelial and mesenchymal markers including Nodal, an embryonic stem cell regulator 
found to be highly expressed in invasive breast cancers. Relative to the control tumors, 
we found epithelial marker, E-cadherin, up-regulated in celeocoxib-treated tumors, 
while mesenchymal markers, Fibronectin, N-cadherin, Snail, Slug, Vimentin, and stem 
cell regulator, Nodal, down-regulated in celecoxib-treated tumors (Figure 3.17). 
 
 
 
 
 Figure 3.15 Celecoxib reduced SUM149 tumor growth in mice. 
Matrigel/ 2 x 106 SUM149 parental
inguinal mammary fat pad 
ppm (n=8) or 500 ppm (n=8) 
tumor formation by week 3. 
over a period of five weeks.
results were graphed using GraphPad Prism version 6.01 software. 
determined by student t-test; 
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 cells were orthotopically injected into the 
of 8 week old female nu/nu mice (n=24) and treated with
celecoxib diet or control (normal) diet (n=8)
Tumor volumes were measured twice/week
 The inhibition of tumor growth rate was calculated and 
*P = 0.0215, **P = 0.0011. 
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Figure 3.16 Celecoxib reduced the levels of PGE2 and PGF2α in orthotopic tumors 
in mice. Resected tumors from the mice were homogenized and cells were 
resuspended and lysed prior to analysis by LC-MS/MS for PGE2 and PGF2α levels (ng) 
relative to total protein (mg) determined by Bradford Assay. 
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Figure 3.17 EMT markers were modulated by celecoxib treatment in SUM149 
xenograft tumors. Epithelial marker E-cadherin and mesenchymal markers 
(Fibronectin, N-cadherin, Snail, Slug, and Vimentin) including stem cell marker, Nodal, 
were measured in SUM149 xenograft tumors by qRT PCR. Celecoxib-treated (250 ppm 
and 500 ppm) mice had increased E-cadherin and reduced mesenchymal markers 
relative to control treated mice. Expression of stem cell regulator, Nodal, was reduced 
in tumors from celecoxib-treated mice. 
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3.3.5 RECOMBINANT HUMAN NODAL MITIGATES THE EFFECTS OF CELECOXIB IN IBC CELLS 
 
 Following our observation that celecoxib treated mice with xenograft SUM149 
tumors downregulated Nodal gene expression, we predicted that the inhibition of COX-
2 in IBC cells has anti-tumorigenic effects by suppressing the Nodal pathway. To 
further investigate COX-2 regulation of Nodal, we investigated the in vitro effects of 
celecoxib on Nodal expression in SUM149 cells by analyzing Nodal gene expression in 
cells cultured in vitro in 3D Matrigel.  We observed PGE2 and PGF2α stimulation to 
increase Nodal expression while celecoxib decreased Nodal expression in SUM149 
cells (Figure 3.18). To determine the potential anti-metastatic effects of celecoxib in 
IBC and regulation of the CSC phenotype, we tested the combination treatment of 
celecoxib with recombinant human Nodal (rhNodal) on the migration, invasion, and 
mammosphere formation of SUM149 cells.  We observed celecoxib to reduce SUM149 
cell migration and invasion (Figure 3.19), and mammosphere formation (Figure 3.20) 
and rhNodal to mitigate celecoxib-mediated inhibition of SUM149 cell migration, 
invasion, and mammosphere formation.  
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Figure 3.18 COX-2 regulates Nodal expression in SUM149 cells in 3D Matrigel 
culture. SUM149 cells were treated with 0.5 µM PGE2 or PGF2α for 48 hours (right 
panel) or treated with celecoxib for 24 hours under 3D Matrigel culture conditions (left 
panel) prior to qRT PCR analysis for Nodal expression levels (n=3). Fold-change in 
Nodal expression was measured relative to control (untreated) SUM149 cells in 3D 
Matrigel culture. 
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Figure 3.19 Recombinant human Nodal mitigated celecoxib-mediated inhibition 
of SUM149 cell migration and invasion. SUM149 cells were pre-treated with 
celecoxib (25 µM) or rhNodal (100 ng/mL), or in combination prior to a 6 hour cell 
migration and 24 hour cell invasion assay (n=3). Cells were stained with 0.1% crystal 
violet/20% methanol solution for 5 minutes then dissolved using 4% sodium 
deoxycholate. Migrated or invaded cells were quantified by luminescence imaging 
using a Perkin-Elmer multilabel plate reader (595 nm). 
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Figure 3.20 Recombinant human Nodal mitigated the effects of celecoxib in 
SUM149 mammosphere formation. SUM149 cells were treated with celecoxib or 
rhNodal alone, or in combination under mammosphere assay conditions. Primary 
mammospheres were passaged following cell counting to re-plate 3 x 104 cells/well for 
secondary mammosphere formation prior to staining with 5 mg/mL MTT reagent and 
quantification by GelCount software. 
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3.4 DISCUSSION 
 
To determine if there was a correlation between EGFR and COX-2 in IBC, we 
performed a cDNA microarray analysis using IBC and non-IBC patient cohorts. Based 
upon the observation of a significantly tighter correlation between EGFR and COX-2 
gene expression in IBC primary compared to non-IBC tumors, and IBC cell lines with 
higher levels of PGE2 and PGF2α, it is conceivable that EGFR-positive IBC cells may 
elicit an increased sensitivity to COX-2 inhibition.  Our observation of EGFR and COX-2 
correlation in IBC and non-IBC is in accordance with other reported links between 
COX-2 and HER family members, such as EGFR and HER2/neu. In a study reported 
by Subbaramaiah et al. the overexpression of HER2 was associated with increased 
levels of COX-2 in human breast cancers, and COX-2 is the functional intermediate 
linking HER2 and aromatase, suggesting that inhibitors of PGE2 synthesis may 
suppress estrogen biosynthesis in breast tissue (107, 108). The significance of COX-2 
in IBC has not been thoroughly investigated and the biological role of COX-2 in EGFR-
expressing IBC is unknown. Our study is the first one to find a correlation between 
EGFR and COX-2 gene expression in an IBC cohort, which suggests the importance of 
COX-2 in EGFR regulation in IBC. IBC is a heterogeneous breast cancer subtype, 
which has not been molecularly differentiated from non-IBC. By gene expression 
profiling, it was reported that IBC is composed of several TNBC molecular subtypes 
described in non-IBC tumors by Lehmann B.D. et al.; however, IBC was not found to be 
specific for either one of the molecular subtypes (9, 17). The pathological complete 
response (pCR) rate was observed to be lower in TN-IBC compared to HR+ and 
HER2+ IBC patients suggesting poorer prognosis in TN-IBC patients (109). By 
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stratifying IBC tumors by TNBC molecular subtypes, we may be able to identify EGFR 
and COX-2 expressing IBC tumors with a specific TNBC molecular subtype.  
Upon observing a correlation between COX-2 and EGFR expression in IBC 
tumors along with elevated PGE2 and PGF2α levels in a panel of IBC cell lines 
compared to non-IBC cell lines, we investigated EGFR-regulation of COX-2 expression 
and activity via EGFR-targeted siRNA or erlotinib treatment with erlotinib. Based on our 
findings, we concluded that the EGFR pathway regulates COX-2 expression and 
activity in IBC cells. It was reported that the regulation of COX-2 expression in breast 
cancer cells  may occur through activation of the PI3K/AKT and MAPK pathways by 
EGFR (110). The regulation of COX-2 could potentially occur through the MAPK 
pathway, which 
transcriptionally 
activates 
expression of 
COX-2 in 
addition to 
several other 
proteins involved 
in breast tumor 
invasion and 
migration. Our 
hypothesized 
model implicates 
the extracellular 
ILLUSTRATION 3.4 A PROPOSED MODEL FOR EGFR/COX-2-
MEDIATED NODAL SIGNALING IN IBC CELLS 
Cross-talk signaling between EGFR and COX-2 may activate ERK1/2 
signaling and stimulate transcription of the NODAL gene through 
phosphorylation of SMAD2 linker region and maintaining a positive 
feedback loop enhancing Nodal signaling in the cell. Deregulation of 
the Nodal pathway leads to enhanced cell motility and invasion. 
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signal-regulated kinase 1/2 (ERK1/2) pathway downstream of EGFR (illustration 3.4).  
Our rationale for speculating that the ERK1/2 pathway may be the key mediator 
for EGFR/COX-2 activity is also based on a prior investigation in our laboratory in 
which inhibition of ERK1/2 but not PI3K/AKT resulted in a synergistic outcome in 
combination with erlotinib treatment of IBC cells (34). Determining whether 
EGFR/COX-2 regulates Nodal in an ERK/1/2 dependent manner remains to be 
determined in future studies.  
We observed that in in vitro studies the COX-2 pathway promoted IBC cell 
migration and invasion, and the invasive-like EMT phenotype. In an in vivo SUM149 
xenograft mouse model, the inhibition of tumor growth by celecoxib occurred 
concomitantly with the down-regulation of EMT-associated events, including decreased 
Nodal expression. Our study demonstrated that the COX-2 pathway regulated the CSC 
population in SUM149 cells as suggested by our results from surrogate cancer stem 
cell assays, mammosphere formation assay, Aldefluor assay, and CD44+/CD24-/low 
staining and flow cytometry analysis. Based on our findings, we concluded the 
suppression of COX-2 to block the progression and metastatic potential of IBC cells 
through down-regulation of the CSC population. Recent studies have linked the 
progression of breast cancer to CSCs and that targeting CSCs might be an effective 
strategy to circumvent drug resistance and reduce tumor recurrence (111). IBC is 
considered to be a highly aggressive breast cancer subtype with a CSC phenotype 
(112), and a poor long-term outcome associated with a high risk of relapse. In addition, 
prior studies have demonstrated a functional role for COX-2 in EMT and breast cancer 
stem cells. It was reported by Bocca C. et al. that hypoxia induced HIF1α expression 
which in turn elevated COX-2 expression and promoted an EMT phenotype in breast 
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cancer cells (60). Relevant to this study, EMT in IBC cells can potentially be triggered 
by elevated COX-2 expression under hypoxic conditions in the presence of growth 
factors and cytokines in the microenvironment.   
We sought to elucidate the mechanism of COX-2-mediated EMT in celecoxib 
treated SUM149 cells. By performing data analysis of celecoxib-modulated gene 
expression using a human EMT RT PCR array kit, we observed down-regulation of 
embryonic stem cell regulator Nodal in SUM149 cells treated with celecoxib for 72 
hours. This result indicated Nodal to be a potential downstream mediator of COX-2-
mediated IBC cell progression (data not shown). We confirmed Nodal regulation by 
COX-2 through in vitro studies and in a SUM149 xenograft mouse model. There is 
evidence that Nodal is highly expressed in aggressive breast cancers, such as poorly 
differentiated breast cancers (113). The potential role of Nodal in the progression of 
IBC was further validated by our observation that recombinant Nodal promoted the 
migration and invasion of IBC cells and the CSC phenotype. These results suggest the 
therapeutic importance of targeting the COX-2 pathway in patients with IBC. However, 
it is not clear if Nodal is a mediator of EGFR-induced COX-2 signaling or is a target of 
COX-2 signaling pathway. We speculate that EGFR regulation of COX-2 in IBC cells 
promotes the CSC phenotype while Nodal signaling, via SMAD or a non-canonical 
pathway, provides positive feedback to COX-2. There is the possibility that 
EGFR/COX-2 regulation of Nodal occurs through MAPK ERK1/2 signaling since 
ERK1/2 is activated downstream of EGFR and has been shown to phosphorylate 
SMAD2 to regulate its nuclear translocation and transcriptional activity (113). A study 
showed that inhibition of ERK1/2 pathway mitigated the activity of the Nodal pathway in 
breast cancer cells. A more in-depth look at the mechanism of EGFR/ COX-2/Nodal in 
101 
 
IBC progression will be addressed in future studies to help enhance our understanding 
of how EGFR/COX-2 axis regulates the CSC phenotype in IBC. Overall, our results 
suggest an important role for COX-2 in promoting EMT and the CSC phenotype in IBC. 
As such, targeting of the COX-2 inflammatory pathway may represent an effective 
therapeutic approach for inhibiting the progression of IBC.  
In summary, we conclude that there is a functional relationship between EGFR 
and COX-2, while a correlative relationship exists between COX-2 and Nodal in IBC 
cells. Further studies are required to determine if COX-2-mediated regulation of Nodal 
is only correlative or if it is causative. This finding could lend to the concept of Nodal as 
a pivotal target or biomarker for COX-2-induced CSC phenotype in IBC cells. 
SB431542, an inhibitor of the canonical Nodal receptors ALK4 and ALK 7, could be 
utilized to block the Nodal pathway and determine whether canonical signaling provides 
a positive feedback to promote COX-2 activity and subsequent release production of 
inflammatory mediators.  
From a clinical perspective targeting COX-2 is efficacious, however there is a 
dilemma of potentially harmful side-effects (e.g. cardiotoxicity and gastrointestinal 
effects) resulting in the long-term use of selective COX-2 inhibitors. Alternatively, the 
EGFR pathway can be inhibited with an EGFR-specific monoclonal antibody, 
panitumumab. In an ongoing clinical study of panitumumab in IBC patients, biomarkers 
(e.g. COX-2, EGFR, and Nodal) will be assessed and pathological complete response 
will also be evaluated at the completion of the study.  The use of panitumumab could 
reduce EGFR-mediated COX-2 activity without the harmful side-effects associated with 
a selective COX-2 inhibitor, leading to an improved response and clinical outcome for 
IBC patients.  
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CHAPTER 4: THE FUTURE OF TARGETED THERAPY IN 
AGGRESSIVE BREAST CANCERS: IBC AND TNBC 
 
 From our translational studies, we conclude that the tumorigenicity and 
invasiveness driven by the CSC population in IBC and TNBC can be modulated by 
COX-2 and RANK signaling. By eradicating the CSC population through inhibition of 
one of these two pathways, we can potentially block the progression of IBC and TNBC 
helping to reduce metastasis and prolong survival in IBC and TNBC patients.  
 This is the first study in which RANKL was found to be an independent 
prognostic factor in RANK positive TNBC patients. The basis of RANK-mediated TNBC 
progression may rely on its interaction with RANKL. Unlike RANK, RANKL is expressed 
at relatively low levels in breast tumor cells, while it is highly expressed in breast tumor 
stroma (114). In TNBC MDA-MB-231 cells, we found the CSC phenotype to be 
regulated by RANK. Our RT2 PCR array analysis revealed stem cell genes modulated 
by the suppression of RANK in MDA-MB-231 cells, which provides us insight into which 
inflammatory pathways might be involved in the RANK-mediated CSC phenotype in 
TNBC. Interestingly, BMP2 and BMP3 were observed to be among the top five stem 
cell genes downregulated by the suppression of RANK. BMPs are members of the 
TGFβ superfamily, which function to regulate CSCs. The downregulation of BMP2 and 
BMP3 gene expression in MDA-MB-231 RANK shRNA cells suggests that RANK is a 
potential target for reducing the invasion and progression of TNBC cells. BMPs 
modulate the breast cancer cellular cytoskeleton and adhesive structures at the cell 
surface to mobilize the cell during migration and invasion (115). The role of BMPs in 
cancer stem cells is not clear, however, it has been documented that BMPs can 
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promote a CSC phenotype, including EMT, through stimulation of the SMAD1/5/8 
pathway. An in vivo TNBC spontaneous metastasis mouse model will allow us to 
investigate the effects of RANK suppression on the invasion and metastasis of TNBC 
cells, and detect stem cell markers modulated downstream of RANKL/RANK in primary 
and metastatic tumors.  
 Preventing the metastasis of TNBC is of high clinical priority for patients and by 
targeting the RANKL/RANK pathway we can potentially block the progression of TNBC. 
From our analysis of RANK and RANKL expression in clinical specimens of TNBC, we 
observed that RANK expression is not a poor prognostic indicator and therefore, we 
need to evaluate RANK and RANKL in a prospective clinical trial. An ongoing phase II 
clinical trial (NCT01952054) at MD Anderson Cancer Center has been initiated to study 
the effects of the RANKL inhibitor, denosumab, on bone metastasis in breast cancer 
patients by monitoring for circulating tumor cells (CTCs) and disseminated tumor cells 
(DTCs) and identifying bone metastasis-relevant biomarkers including RANK and 
RANKL. In this particular clinical trial, the patient cohort will be estrogen receptor (ER)-
positive advanced breast cancer patients. ER-dependent breast tumors have a 
tendency to develop bone metastases at a two-fold higher rate compared to non-ER 
breast tumors (116). Although this particular clinical trial is not targeted at TNBC 
patients, findings from this study may elude to whether the co-expression of RANK and 
RANKL in breast tumors is a predictive indicator for poorer outcome and if denosumab-
treated patients have improved skeletal-disease free survival and reduced bone 
metastases. To evaluate RANK and RANKL expression and the efficacy of denosumab 
in a TNBC subtype-specific (BL1, BL2, M, MSL, LAR, and IM) cohort, patients would be 
randomly assigned to receive either denosumab or placebo (control) treatment. By 
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stratifying TNBC patients, based on the six gene expression profiles described by 
Lehmann BD et al.(12), we can determine if there is an association between TNBC 
subtype and favorable response to denosumab therapy. Findings from this clinical 
study will provide insight into whether targeting the RANKL/RANK pathway in TNBC is 
clinically relevant and if blocking the RANKL/RANK pathway will result in reduced 
metastasis and improved clinical outcome. 
 In IBC, we observed a positive regulation of COX-2 by EGFR in IBC, and made 
a novel finding that the COX-2 pathway regulates the expression of Nodal and the CSC 
phenotype of IBC cells.  To this end, we conclude that inhibition of the Nodal pathway 
could be an effective strategy to eradicate CSCs in COX-2 expressing tumors. 
However, the mechanism of Nodal regulation by COX-2 is yet to be validated and 
whether targeting the Nodal pathway will suppress IBC tumorigenicity and metastasis 
remains unknown. We will further investigate the requirement for COX-2 and Nodal in 
tumor progression by assessing the efficacy of a combined celecoxib and SB431542 
(an inhibitor of canonical Nodal signaling) therapy in IBC cells. EGFR, COX-2, and 
Nodal are linked with inflammation in breast cancer as they each are upstream 
regulators of transcription activators that promote the gene expression of several 
inflammatory molecules involved in breast cancer progression. To study the role of 
inflammation in IBC, a future clinical trial for the treatment of IBC patients will 
investigate the effects of targeting the COX-2 pathway via EP4 receptor inhibitor, and 
identify novel inflammatory markers modulated by the inhibition of the EP4 receptor. 
This study will allow us to investigate a novel therapeutic approach to targeting COX-2-
mediated inflammatory response in IBC.  
105 
 
 Potentially, the RANK and COX-2 pathways can converge to induce an 
inflammatory response in IBC and TNBC. We found several stem cell genes modulated 
by the suppression of RANK in the TNBC cells that are linked with inflammatory 
signaling pathways activated in breast cancer cells. The RANKL/RANK can activate 
NFkB transcriptional activity, leading to the induction of COX-2 gene expression. In turn, 
activation of the COX-2 pathway can stimulate the production and secretion of PGE2, 
leading to an upregulation of RANKL and RANK gene expression (117). In addition to 
NF-kB, the AP-1 transcription factor, which activates the expression of the COX-2 gene, 
PTGS2, can be upregulated by the JNK pathway downstream of RANKL/RANK (117).  
While it is not clear which downstream pathway is involved in the regulation of 
RANKL/RANK activity of TNBC cells, however, it can be speculated that the 
inflammatory signaling pathways mediate the transformation and aggressive phenotype 
of IBC and TNBC   
 Collectively, RANKL and EGFR are promising targets for the development of 
novel strategies to prevent or inhibit TNBC and IBC progression. Therapeutic targeting 
of RANKL and EGFR using humanized monoclonal antibodies, denosumab and 
panitumumab, may lead to the suppression of the inflammatory mediators produced by 
RANKL/RANK and EGFR/COX-2 signaling. Abrogated signaling through these 
receptors is concomitant with the downregulation of the tumor-promoting activity of 
CSCs in IBC and TNBC. Measurement of the efficacy of these antibodies to target the 
CSC population will occur through the detection of circulating tumor cells (CTCs) in the 
peripheral blood, described as EPCAM+/CD45- (118), and disseminated tumor cells 
(DTCs) or epithelial cells expressing CD326+CD45low localized to the bone can be 
evaluated based on multiparameter flow cytometry analysis of CD44+CD24- and ALDH 
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activity (119). On the basis of our data, we expect that TNBC and IBC patients treated 
with denosumab or panitumumab will reduce COX-2, EGFR and Nodal activity in 
primary breast tumors, and reduce the number of CTCs in peripheral blood and DTCs 
in bone marrow. We envision that such a therapy may prevent patient morbidity 
through the elimination of de novo metastasis and improved long-term survival. 
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